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SUMMARY 
With over 50,000 deaths and 80,000 disorders annually in the United States resulting 
from traumatic brain injury (TBI), there is a demand for improved therapeutic strategies.  
Cell transplantation offers the potential to treat TBI by targeting multiple mechanisms in 
a sustained fashion.  However, efforts are needed to improve survival and integration of 
transplanted cells, and ultimately enhance functional recovery.  Using tissue engineering 
strategies, we aimed to mimic key aspects of fetal tissue grafts by combining neural stem 
cells with a fibronectin or laminin based scaffold that could be delivered to the injured 
brain in a minimally invasive fashion.  We found that the incorporation of extracellular 
matrix proteins into a cell transplantation paradigm led to improved donor cell survival 
and restored cognitive ability for treated animals.  To begin to examine how fibronectin 
and laminin mediate these improvements, we first examined the endogenous role of these 
two proteins in the injured brain.  Using a clinically-relevant model of TBI, we found 
both proteins are increased in the injured brain at acute time points.  The spatial 
localization of fibronectin and laminin with specific support cells in the brain suggests a 
role for these proteins in repair, warranting further investigation.  Using conditional 
plasma fibronectin knockout animals, we found that fibronectin is neuroprotective to the 
traumatically injured brain.  Specifically, injured fibronectin knockout animals had more 
severe motor and cognitive deficits, increased cell death, and decreased retention of 
phagocytic cells compared to injured wild type animals.  Thus, we have identified novel 
therapeutic treatments for TBI which utilize tissue engineered transplants and/or exploit 






Traumatic Brain Injury 
Traumatic brain injury (TBI) results from a sudden and external physical impact to the 
head, and often leads to motor (e.g., loss of ambulation, balance, coordination, fine motor 
skills, strength, and endurance) and cognitive (e.g., loss of communication, information 
processing, memory, and perceptual skills) impairment.  Annually, there are over 50,000 
deaths and 80,000 disabilities resulting from TBI in the United States alone (Langlios, 
2004; Thurman et al., 1999).  The economical impact, costing over $4.5 billion (in direct 
costs) per year (Max et al., 1991), as well as the health and sociological implications 
prompt the demand for clinically effective treatments.   
 
The physical impact to the brain tissue initially causes necrotic cell death in the 
underlying tissue, followed by apoptotic cell death in surrounding tissue due to multiple 
subsequent events such as edema, ischemia, excitotoxicity, increase in free radicals, and 
altered gene expression (for review, see McIntosh et al., 1998 and/or Verma, 2000).  Both 
primary and secondary insults initiate a glial response, which acutely acts to sequester 
and clean debris at the injury site.  Cellular components of the glial scar include reactive 
astrocytes, which help buffer excess glutamate and secrete neurotrophic factors, and 
activated microglia, which along with monocyte-derived macrophages, clear out dead 
tissue.  However, extracellular components of the glial scar that forms adjacent to the 
injury site have been found to inhibit neurite extension (e.g., chondroitin sulphate 
proteoglycans (CSPGs), Nogo protein), thus limiting regeneration (for review, see 
Properzi et al., 2003).  It has also been appreciated recently that the brain may be 
attempting to repair through developmental processes, as evidenced by the increases in 
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neurogenesis and angiogenesis that occur following TBI (Dash et al., 2001; Kernie et al., 
2001; Ramaswamy et al., 2005).  The schematic in Figure 1.1 summarizes these post-
TBI events.  This evolution of the brain injury response exemplifies the dynamic 
interplay between events promoting repair and regeneration competing with mechanisms 
of damage and inhibition.  Ideal treatment strategies will exploit and complement native 






Figure 1.1: Schematic of events following focal traumatic brain injury  
Mechanisms of damage and inhibition or regeneration (in red boxes) occur alongside 
permissive and reparative mechanisms (in green boxes).  Better understanding 
mechanisms on both sides of the response can aid in the development of more effective 






















excitotoxicity, ischemia, ↑ free 
radical, apoptosis 
Initial Glial Response: phagocytosis,   
↓ excitotoxicity, sequester injury site  
Long-term Glial Scar: inhibits 
neurite outgrowth/regeneration 
Repair Attempts: neurogenesis, 
angiogenesis, ↑ in beneficial ECM proteins
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Dual Role of Inflammation in Traumatic Brain Injury 
While the brain is considered immune-privileged (due to the tight regulation of the CNS 
microenvironment which largely excludes blood leukocytes from entering), immune 
responses occur during pathological conditions (Perry et al., 1997).  In TBI, the initial 
release of cell contents from the primary necrosis initiates an inflammatory reaction.  
While inflammation occurring in the brain is associated with deleterious events, the 
beneficial role of inflammation in TBI has gained appreciation (Correale and Villa, 2004; 
Lenzlinger et al., 2001; Morganti-Kossmann et al., 2002; Schwartz, 2000).  The major 
events of inflammation following TBI are summarized here with an emphasis on the dual 
nature of this endogenous immune response.   
 
The three major classes of protein mediators of inflammation are cytokines, chemokines, 
and complement proteins.  Pro-inflammatory cytokines (e.g., tumor necrosis factor 
(TNF), interleukins-1 and -6) are released within minutes following TBI (Morganti-
Kossmann et al., 2002).  Studies with specific cytokine knockout mice, as well as in vitro 
studies indicate that these cytokines may have acute deleterious effects (e.g., blood-brain 
barrier (BBB) dysfunction, promotion of neuronal death), but are beneficial at later time 
points (e.g., induce synthesis of anti-inflammatory cytokines, induce neurotrophic factors, 
promote proliferation of oligodendrocyte precursor cells which may help in 
remyelination) (Morganti-Kossmann et al., 2002).  Neurons and glial cells (astrocytes, 
microglia, and oligodendrocytes) can produce both chemokines (e.g., TNFα, interferon-γ) 
and complement proteins (e.g., C3, C5), and have receptors for these proteins.  In a 
similar dual role, chemokines and complement proteins are involved in acute BBB 
dysfunction and edema, while these proteins eventually lead to increased nerve growth 
factor production in astrocytes and microglia.  Furthermore, complement proteins have 
been found to protect neurons from excitotoxicity-induced apoptosis and promote 
opsonization (Schmidt et al., 2005).   
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With respect to the cellular aspect of the inflammatory response, microglia (resident brain 
immune cells) are the first to respond (minutes to hours) by proliferating, and becoming 
activated microglia which migrate to the area of injury, where they essentially function as 
macrophages (Kato and Walz, 2000; Ladeby et al., 2005).  In a traumatic injury, which is 
associated with increased BBB permeability, leukocytes from the blood can pass through 
the endothelium at the site of injury; and this process is mediated by cytokines, 
chemokines, and complement proteins (Schmidt et al., 2005).  Neutrophils are the first to 
infiltrate (hours to days), followed by monocytes (days) (Kato and Walz, 2000).  Again, 
there are both beneficial and deleterious roles for these immune cells.  The oxidative 
burst of neutrophils and macrophages is harmful because of the release of oxygen free 
radicals and neurotoxic enzymes (Schmidt et al., 2005), however, both activated 
microglia and monocyte-derived macrophages aid in clearing debris from dead/damaged 
cells via phagocytosis (Hauwel et al., 2005).  Because of the dual nature of the 
inflammatory response, treatments for TBI that target specific cells or proteins involved 
in the inflammation response may not be ideal (McIntosh et al., 1998).   
 
Clinical Treatments for Traumatic Brain Injury 
Current treatment methods in clinical practice primarily aim to reduce intracranial 
pressure in an effort to minimize brain damage caused by swelling.  Examples include 
moderate hypocapnia and mannitol (first line measures), followed by barbiturates, 
moderate hypothermia, or a decompressive craniectomy (second line measures) if early 
attempts fail (Sahuquillo and Arikan, 2006).  However, these therapies have a modest 
effect on acute brain damage or subsequent cell death pathways which lead to functional 
impairment (Roberts et al., 1998).  Furthermore, these treatments do not provide 
sustained efforts to promote repair or regeneration.  Since the majority of TBI patients are 
young adults, there is a demand for chronic treatments that would prevent further brain 
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damage and help repair damage that has already occurred.  Treatment approaches under 
investigation for TBI in the past several years aim to target one or more of the 
pathological events following TBI in an effort to rescue cells or promote repair and 
regeneration.  While many prospective treatments seemed promising in animal models, 
results in clinical trials have been mixed at best.  For example, excitotoxicity results from 
excess glutamate released from necrotic cells over stimulating neurons (primarily through 
NMDA receptors), causing increased intracellular calcium levels and ultimately cell 
death; and targeting excitotoxicity showed therapeutic potential in animal models.  
However, various treatments that mediate along this path, such as glutamate antagonists, 
were not found to be effective for humans with TBI (Ikonomidou and Turski, 2002; 
Willis et al., 2004).  Similar results occurred with other investigational drugs including 
free radical scavengers and steroids (Narayan et al., 2002).  These treatments may have 
failed in the clinic because they target pathways that are both deleterious and beneficial, 
thus the dosage and time of treatment are critical to not interfere with normal homeostasis 
or reparative mechanisms in the brain.  Furthermore, these treatments targeted single 
mechanisms, which may not be enough in light of the multi-faceted pathology.  Therapies 
that currently seem more promising, such as hypothermia or progesterone administration, 
address multiple pathological events.     
 
Experimental Model – Controlled Cortical Impact Injury 
The majority of traumatic injuries to the head occur in falls, followed by motor vehicle 
accidents, making blunt trauma by far the most prevalent type of TBI (Langlios, 2004).  
Researchers model this type of focal injury by impacting the exposed mammalian cortex, 
typically using one of the following experimental models (listed in chronological order of 
their development): weight drop, fluid percussion, or controlled cortical impact (CCI).  
The CCI injury, a controlled mechanical compression to the cortical surface produces 
consistent and reproducible injuries, has a low mortality rate compared to the other 
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models, and has a well-characterized pathophysiology that closely approximates events 
seen in human TBI, including acute subdural hematoma, BBB dysfunction, and edema 
(Cernak, 2005; Dixon et al., 1991; Morales et al., 2005).  It has also been shown that 
using the CCI model in mice produces long-term motor and cognitive deficits that mimic 
certain aspects of clinical TBI (Fox et al., 1998; Shear et al., 2004).  Using this model, the 
experimenter can control velocity, depth, duration, and angle of the impact; though the 
velocity and depth are the best predictors of injury severity (Cernak, 2005; Morales et al., 
2005).  An injury to the cortex, which impacts the mouse brain at a velocity of 6.0 m/sec 
and deforms the brain 1 mm is considered moderate, and is associated with both cortical 
and subcortical damage and produces sustained sensory/motor and spatial learning 
deficits (Fox et al., 1998).  The CCI injury model in mice is utilized throughout this 
dissertation work, using a custom-built pneumatically-driven impactor device (see 
schematic in Figure 1.2) and with the following parameters to obtain moderate, unilateral 
injuries: velocity = 6.0 m/sec, depth = 1 mm below dura, duration in brain = 150 msec, 


























Figure 1.2: Schematic of pneumatically-driven piston used for controlled cortical 
impact injuries   
Using the custom-built device depicted in this figure, a controlled impact is applied to the 
exposed rodent cortex.  Air flow is represented by blue lines, and red lines symbolize 
electrical transmission.  Briefly, compressed breathable air, regulated to 110 psi, moves 
through one of two ports in the double solenoid valve (shown in green).  Air leaving one 
side will push air into the top of the piston, driving the piston down, while the other side 
has the opposing affect.  The switch between the two movements is controlled via 
LabVIEW software (National Instruments, Austin, TX), which also reads from a linear 
variable displacement transducer connected in series with the piston to measure velocity 
and duration of the impact.   
Air cylinder 
120 V
   110 psi 
LVDT 









Relevant Extracellular Matrix Proteins Involved in TBI Response 
The levels of various extracellular matrix (ECM) proteins increase following TBI.  We 
are interested in investigating those proteins that may be involved in repair or 
regeneration.  Furthermore, we are interested in ECM proteins which may be exploited 
for use in tissue engineered constructs containing neural stem cells (NSC) in an effort to 
recapitulate fetal-like tissue for transplantation after TBI.  Both fibronectin (FN) and 
laminin (LN) play a major role in neural development and are found in increased levels 
following injury, where they potentially play a reparative role.  Thus, these proteins are 
the focus of this dissertation work.  
 
Fibronectin 
Fibronectin, a large (~440kDa) glycoprotein, is a common adhesive protein of the 
interstitial matrix (for review, see (Pankov and Yamada, 2002)).  There are 20 different 
FN isoforms in humans, generated by alternative splicing of a single FN gene.  The 
majority of the splicing patterns are cell-type specific, and give rise to a number of 
different cellular FN isoforms, which are found immobilized in ECM.  Another type of 
FN is plasma FN (pFN), which is primarily made by hepatocytes and secreted as a 
soluble form into the blood plasma (Owens and Cimino, 1982).   
 
Fibronectin interacts with cells primarily via integrin receptors, and this binding signals a 
sequence of events including changes in gene expression, cell survival, proliferation, 
differentiation, and migration (for review, see (Danen and Yamada, 2001)).  While many 
integrins have been shown to bind FN, including α3β1, α4β1, α8β1, αΙΙbβ3, αvβ1, αvβ3, 
αvβ5 and αvβ6, the classic FN-binding integrin is  α5β1 (Sonnenberg, 1993).  Fibronectin 
predominately binds to the  α5β1 integrin (as well as others) via the Arg-Gly-Asp (RGD) 
amino acid sequence located in the central binding domain, and this is synergistically 
enhanced by binding to the Pro-His-Ser-Arg-Asn (PHSRN) sequence (Aota et al., 1994).  
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The binding of FN to α5β1 promotes cell adhesion and triggers events such as cell 
migration and signal transduction (Akiyama, 1996).   
 
Fibronectin in the Normal and Injured Brain 
Fibronectin is crucial for embryogenesis (George et al., 1993), and is involved in the 
developing nervous system (Reichardt and Tomaselli, 1991).   Fibronectin promotes both 
the survival and migration of neural crest cells (Henderson and Copp, 1997; Testaz and 
Duband, 2001), and also supports migration of neurons to different cortical regions 
(Sheppard et al., 1995).  Furthermore, FN promotes neurite extension and synapse 
formation in the developing brain (Einheber et al., 1996).  While FN is largely absent in 
the adult brain (Bellail et al., 2004; Maenpaa et al., 1997), levels increase following brain 
injury.  Human TBI studies have shown an increase in FN post-injury (Liu and Sturner, 
1988), and an increase in FN has also been seen in various brain injury models including 
penetrating stab wound (Egan and Vijayan, 1991; Mizutani and Kimura, 1987; Pasinetti 
et al., 1993), cortical cold injury (Nag et al., 1997; Suzuki and Choi, 1990), kainic acid 
lesion (Hertel et al., 2000).  Since the elevated FN levels after TBI are largely due to an 
increase in BBB permeability (Nag et al., 1997) and cellular FN is not expressed in 
wounded tissue following ischemic brain injury (Sakai et al., 2001), it is hypothesized 
that the majority of FN expression after brain injury is plasma borne.   
 
It has been suggested that FN plays a role in repair following TBI (Egan and Vijayan, 
1991; Liu and Sturner, 1988; Nag et al., 1997), though this has not been experimentally 
verified.  However, following cerebral ischemia, Sakai et al. (2001) showed that pFN null 
mice have greater lesion size, increased number of apoptotic cells, and decreased Bcl-2 
expression, indicating that pFN is neuroprotective in brain ischemia.  Furthermore, 
exogenous functional FN peptides have also been shown to reduce polymorphic 
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leukocyte accumulation, infarct size and improve neurological outcome when 
administered intravenously for experimental cerebral ischemia (Yanaka et al., 1996). 
 
Fibronectin in Wound Repair and Phagocytosis  
Fibronectin has been extensively studied in peripheral wound healing, and pFN is a 
potent stimulator of the wound healing process (Lariviere et al., 2003).  The two major 
roles for FN in would healing are in the formation of blood clots (both as a scaffold for 
other matrix proteins and as a cell attractant) and opsonization, which is the process by 
which foreign bodies are made more amenable to phagocytosis (for review, see (Clark, 
1988)).  For the purposes of the dissertation work presented here, we will focus on the 
latter.  Fibronectin is a well-known opsonin and mediates removal of several types of 
foreign bacteria (Mosser, 1994; Shinji et al., 2003).  Furthermore, FN also opsonizes 
tissue debris for removal by phagocytes (Martin et al., 1988).  Following most types of 
trauma, pFN levels are depressed due to the binding of pFN to the gelatinous injured 
tissue (La Celle et al., 1990; Martin et al., 1988; Reese et al., 1982).  In addition to its 
opsonic functions at the site of injury, FN aids in macrophage recruitment to this injured 
tissue.  Fibronectin fragments are chemoattractants for monocytes (Proctor, 1987), and 
FN enhances adhesion and migration of monocytes via β1 integrin binding (Kao et al., 
2001; Meng and Lowell, 1998).  Upon entering the site of injured tissue, monocytes 
differentiate into macrophages, which correlates with increased expression of FN integrin 
receptors (Akimov and Belkin, 2001; Mograbi et al., 1999).  All of these findings indicate 
FN is a critical player in the inflammatory response with respect to phagocytosis of 
injured tissue.   
 
More specific to brain injury, FN regulates microglial cell behavior.  Because the brain is 
protected by the tight junctions of the BBB, leukocytes from the blood typically cannot 
enter (Perry et al., 1997).  Microglia are the resident immune cells available to respond 
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quickly in the immune-privileged brain.  As microglia become activated (taking on more 
of a phagocytic phenotype), FN integrin expression increases (Milner and Campbell, 
2003).  Binding to FN promotes microglial cell proliferation, adhesion and migration 
(Liao et al., 2005; Nasu-Tada et al., 2005), all of which are involved in recruitment of 
microglia to injured brain regions.  Fibronectin binding also increases microglial 
secretion of nerve growth factor and transforming growth factor-beta (Liao et al., 2005), 
both of which have beneficial functions in the injured brain (Lenzlinger et al., 2001; 
Sinson et al., 1997). 
 
Fibronectin and Apoptosis 
Anoikis refers to increased apoptosis in response to the absence of cell-ECM interactions.  
Fibronectin has been shown to be anti-apoptotic in various in vitro cell systems including 
umbilical vein endothelial cells (Fukai et al., 1998), Chinese hamster ovaries (Matter and 
Ruoslahti, 2001; Zhang et al., 1995), and prostate cancer cells (Morgan et al., 2000).  
More specific to the nervous system, Gibson et al. (2005) showed that FN is anti-
apoptotic for Ntera2 neurons in vitro.  In all cases, the reduction in cellular apoptosis was 
dependent on FN binding via the α5β1 integrin.  Furthermore, Fukai et al. (1998), Matter 
and Ruoslahti (2001), and Zhange et al. (1995) showed that FN-α5β1 integrin binding 
causes increased expression of the anti-apoptotic molecule, Bcl-2.  While Bcl-2 levels 
were not examined in the in vitro study of neuronal apoptosis, Sakai et al. (2001) reported 
that mice deficient in pFN have both increased apoptosis and decreased Bcl-2 expression 
following cerebral ischemia.  In TBI, decreases in Bcl-2 precede apoptosis in TBI 
(Raghupathi et al., 2002) and overexpression of Bcl-2 has been found to be 
neuroprotective (Nakamura et al., 1999), indicating that FN binding may mediate Bcl-2 





Laminin, a trimeric glycoprotein ranging from 500-1000 kDa, is the major adhesive 
protein of the basal lamina (Colognato and Yurchenco, 2000).  There are 16 known LN 
isoforms (12 found in mammals), made from various combinations of the five α, three β, 
and three γ subunits (Suzuki et al., 2005).  The LNs are named (LN-1 to 16) based on the 
specific combination of these subunits.  Recently, a simplified trimer nomenclature was 
proposed to name the LNs using the numbers associated with each subunit (Aumailley et 
al., 2005), thus both names are provided in the text below.  The most studied cellular 
receptors for LNs are integrins, including α1β1, α2β1, α3β1, α6β1, α7β1, α6β4; but other 
receptors include α-dystroglycan, and syndecans (Suzuki et al., 2005).   
 
Laminin in the Normal and Injured Brain  
Laminin plays an important role in neural development (Reichardt and Tomaselli, 1991).  
Laminin-1 (a.k.a. laminin-111), the primary LN type in early embryogenesis, promotes 
cell survival and migration in the developing nervous system (Liesi, 1992; Perris and 
Perissinotto, 2000), and both LN-1 and LN-2 (a.k.a. laminin-211) promote neurite 
outgrowth (Colognato and Yurchenco, 2000).  In the mature brain, LN-10 (a.k.a. laminin-
511) is found in the hippocampus and protects hippocampal neurons from excitotoxic 
lesions (Chen et al., 2003; Indyk et al., 2003), and laminin α2 subunit (likely in LN-2) is 
found in close association with dendritic spines in the hippocampus, and may be involved 
in synaptogenesis (Tian et al., 1997).  Laminin-5 (a.k.a. laminin-332) is a major 
component of the ECM of the BBB, where it can be found in the basement membrane of 
blood vessels (along with LN-1 (Hagg et al., 1997)) and interacts with integrins on both 
endothelial cells and astrocytes (Wagner and Gardner, 2000).  There is an increase in LN 
levels (either LN-1 or not specified) in the adult brain following clinical brain injury 
(Hausmann and Betz, 2000) and in experimental injuries, including cortical cold injury 
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(Kakinuma et al., 1998; Suzuki and Choi, 1990) and penetrating stab wound (Szabo and 
Kalman, 2004).    
 
While the role of this increase in LN levels is unknown, it is thought to be reparative in 
nature (Kakinuma et al., 1998), based on the supportive functions of LN in development.  
Laminin has also previously been exploited as a treatment for brain injury.  Functional 
LN peptides administered intravenously after cerebral ischemia led to reduced 
polymorphic leukocyte accumulation and infarct size and improved neurological outcome 
(Yanaka et al., 1997).  Furthermore, LN-based hydrogels implanted into a brain cavity 
encouraged cell infiltration and angiogenesis and reduced glial scar formation (Hou et al., 
2005).  The use of LN as treatment provides further evidence for a beneficial role after 
brain injury.   
 
Neural Transplantation and Tissue Engineering 
Evidence suggests that cells in the CNS can regenerate if they are in the proper 
environment (David and Aguayo, 1981).  Transplanting cells may help approximate this 
environment and mediate repair and recovery through trophic support, cell-cell contact 
induced signaling, and/or replacing cells lost to injury. 
 
Fetal Tissue Transplantation 
Transplantation of fetal tissue has been shown to promote recovery of central nervous 
system (CNS) injury as well as neurodegenerative diseases (for review, see Koutouzis et 
al., 1994; Subramanian, 2001).  Specific to brain injury, fetal tissue grafts have been 
shown to improve functional recovery following various models of TBI.  For example, 
fetal frontal cortical tissue transplants promoted cognitive recovery following frontal 
cortical lesions (Labbe et al., 1983).  Also, fetal cortical tissue transplanted following 
fluid percussion injury led to improved motor and cognitive recovery (Sinson et al., 
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1996).  Unfortunately, there are some limitations to the clinical use of fetal tissue 
transplants (for review, see Stein, 1991 and/or Stein and Glasier, 1995).   There are both 
ethical and availability issues with using fetal sources.  From a technical standpoint, 
tissue pieces are difficult to keep viable in vitro, making an “off-the-shelf” treatment 
unlikely.  In addition, intracranial injection of tissue pieces requires potentially invasive 
surgical procedures.  Based on these considerations, transplantation of cells from other 
sources offers a promising alternative.   
 
Cell Transplantation  
Transplantation of cells in suspension may overcome many of the limitations associated 
with using fetal tissue, and thus may be more clinically feasible.  For example, 
transplantation of cells offers a potentially renewable treatment source and surgical 
procedures may be less invasive compared to transplanting tissue pieces.  In particular, 
stem cells are an attractive transplantation candidate due to their ability to proliferate 
extensively in vitro and their multipotential characteristics.  Previous work in our 
laboratory has determined that transplanting NSC into the ipsilateral striatum after TBI 
results in sustained motor and cognitive improvement (Shear et al., 2004).  There are 
numerous other investigations into cell transplantation paradigms for TBI with differing 
cell types and delivery times / locations with varying responses of donor cell function and 
effects on host recovery (for review, see Schouten et al., 2004).  In addition to 
investigating these factors, the method of delivery must be considered, as a common 
problem with cell transplants is their limited survival and interaction with host cells, 
particularly compared to fetal tissue grafts.  Studies that directly compare cells in 
suspension and tissue pieces have shown that donor cells transplanted in the tissue pieces 
had significantly improved survival; and furthermore, animals receiving the tissue pieces 
had significantly better functional outcome compared to those treated with cell 
suspension grafts  (Clarkson et al., 1998; Hoovler and Wrathall, 1991; Sinson et al., 
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1996).  This enhanced donor cell survival for transplantations of intact tissue may be due 
to the presence of three-dimensional structure and a higher accessibility of extracellular 
adhesive proteins for the donor cells to attach.  Cell transplantation has already shown 
promise in the clinic for treating severe TBI (Seledtsov et al., 2005), and it is important to 
move cell transplantation research towards improving survival and integration of donor 
cells in an effort to further advance cell transplantation therapy.  
 
Neural Stem Cells 
Stem cells are receiving attention as candidate cells for transplantation, due largely to the 
proliferative and pluri-/multipotent nature of these cells.  The fate of these cells is 
dictated by both in vitro preparation and the host environment.  This is important because 
multipotent stem cells can adapt to the “needs” of the host tissue (Yandava et al., 1999).  
Neural stem cells are multipotent stem cells that have the capacity to differentiate into the 
major cells in the CNS: neurons, astrocytes, and oligodendrocytes, and have many 
potential applications in CNS transplantation.  Neural stem cells persist in the adult brain 
(Johansson et al., 1999; Rietze et al., 2001) and contribute to neurogenesis that occurs 
throughout adult mammalian life in the olfactory and hippocampal regions (Dash et al., 
2001; Johansson et al., 1999).  Furthermore, the rate of neuro- and gliogenesis increases 
following injury (Dash et al., 2001; Johansson et al., 1999; Kernie et al., 2001; 
Ramaswamy et al., 2005).  This is thought to be an attempt at self-repair and plasticity, 
but regeneration in the brain is limited due to mechanisms that are not completely 
understood, but are attributed to an inhibitory environment.  Transplanting NSC into the 
injured brain may augment the neuro- and gliogenic environment that the brain inherently 





Neural Stem Cells and Fibronectin and Laminin 
In the developing nervous system, NSC utilize both FN and LN for survival and 
migration signals (Henderson and Copp, 1997; Testaz and Duband, 2001).  For example, 
previous work in our laboratory examined the behavior of NSC in vitro, and found that 
adhesion and migration on both FN and LN is significantly higher than other ECM 
proteins, including collagen types I and IV, and CSPG (Tate et al., 2004).  Furthermore, 
we showed that these behaviors are primarily mediated through α5β1 and α6β1 integrin 
binding to FN and LN, respectively (Tate et al., 2004).  In addition, β1 integrins are also 
critical to NSC survival and proliferation (Leone et al., 2005).  Based on this in vitro 
evidence and the roles of FN and LN in development, transplanting NSC with FN or LN 
may aid in survival and integration of these cells in the injured brain.   
 
Neural Tissue Engineering in the Brain 
Tissue engineering offers the ability to repair or replace lost tissue using a multi-faceted 
approach.  The classic description of a tissue engineered construct is the combination of 
cells with an appropriate scaffold that provides both mechanical and chemical support.  
The addition of the cellular component can occur ex vivo or the scaffold can recruit cells 
in the body.  Specific combinations of cells and scaffolds are designed to meet the needs 
of the physiologic and pathologic system of interest.  To date, there have been several 
efforts to utilize tissue engineering approaches in the nervous system.  Focusing on the 
brain, tissue engineering approaches have ranged from implanting encapsulated nerve 
growth factor secreting cells to treat Alzheimer’s disease (Winn et al., 1996) to 
implanting NSC within porous polyglycolic acid scaffolds to treat hypoxia-ischemia 
(Park et al., 2002).   
 
We are developing a construct containing NSC and a bioactive scaffold utilizing ECM 
proteins that can be delivered in a minimally invasive fashion, for the purpose of 
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increasing donor cell survival and integration within the host tissue, thereby improving 
repair and recovery.  We have shown that there is increased donor cell migration when 
NSC are transplanted within a FN/collagen I (FN/CnI) scaffold compared to NSC 
transplanted alone after TBI (Tate et al., 2002).  This increased migration to areas of 
secondary insult (e.g., fimbria-fornix in the hippocampus) implies these cells are 
responding to cues of the injured brain, indicating that delivery of NSC with specific 
ECM proteins improves integration with the host tissue.  Moreover, we can infer that the 
enhanced migration is due to the presence of FN in the scaffold since these cells have 
increased in vitro adhesion and migration on FN, but not on CnI (compared to tissue 
culture plastic) (Tate et al., 2004).  Utilization of appropriate ECM proteins in cell 
transplantation paradigms may be crucial to increase donor cell survival and integration, 




LAMININ AND FIBRONECTIN ENHANCE SURVIVAL OF 
NEURAL STEM CELLS TRANSPLANTED INTO THE INJURED 
BRAIN, RESULTING IN FUNCTIONAL RECOVERY 
 
Abstract 
Cell transplantation offers the potential to treat central nervous system injuries, largely 
because multiple mechanisms can be targeted in a sustained fashion.  It is crucial that 
cells are transplanted in an environment that is favorable for their extended survival and 
integration with the host tissue.  Given the success of using fetal tissue grafts for 
traumatic brain injury, it may be beneficial to mimic key aspects of this tissue (e.g., three-
dimensionality, extracellular matrix support) to deliver cells.  Extracellular matrix 
proteins such as fibronectin and laminin are involved in neural development and may 
provide adhesive support for donor cells and mediate cell signaling events.  In this study, 
neural stem cells were transplanted into the traumatically injured mouse brain within a 
tissue engineered construct containing either a laminin- or fibronectin-based scaffold.  
Behavioral results indicated that mice receiving neural stem cells within the laminin-
based scaffold perform better than untreated mice on the Morris water maze task.  
Furthermore, by 8 weeks post-transplant, cells delivered within the fibronectin-based 
scaffold showed improved survival compared to those transplanted in media alone, and 
this was more exaggerated for cells delivered within the laminin-based scaffold, which 
correlates with the behavioral results.  Initial delivery conditions are an important 
consideration, and the use of appropriate extracellular matrix based scaffolds can be 




Traumatic brain injury (TBI) remains a major health problem with over 1.4 million new 
cases of TBI annually in the United States alone (Langlios, 2004), however there is 
currently no clinical treatment available that aids in repair or regeneration.  Considering 
the complex and dynamic milieu of the injured brain, cell transplantation is an attractive 
treatment option because multiple therapeutic mechanisms can be targeted in a sustained 
fashion.  Moreover, cells, particularly stem cells, are adaptable to their environment and 
can communicate with the injured brain cells.  The robust and plastic nature of stem cells 
makes them favorable candidates in cell transplantation paradigms.  We are interested in 
utilizing neural stem cells (NSC), which are multipotential cells capable of differentiating 
into the major cell types along the neural lineage, specifically, neurons, astrocytes, and 
oligodendrocytes.   
 
One important consideration for cell transplantation in the central nervous system (CNS) 
is the preparation and delivery of transplants.   Studies have shown that transplantation of 
tissue pieces have better graft survival and lead to improved behavioral recovery 
compared to cell suspension grafts (Clarkson et al., 1998; Hoovler and Wrathall, 1991).  
For TBI, transplanting fetal tissue pieces to the injured brain has been shown to 
significantly improve behavioral recovery (Labbe et al., 1983; Sinson et al., 1996).  
However, delivery of intact tissue is more invasive than injections of cell suspensions.  
Furthermore, ethical considerations and availability issues associated with transplanting 
fetal tissue prompt the demand to improve cell suspension transplants.  Many aspects of 
the intact tissue may contribute to the success of this treatment including three-
dimensionality, cell-cell support (with multiple cell types), growth factor cues, and cell-
matrix support.  Using tissue engineering, a subset of these features can be recapitulated.  
In this study, we examined augmenting delivery of NSC with an extracellular matrix 
(ECM) protein-based scaffold support.  The two ECM proteins that we examined were 
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fibronectin (FN) and laminin (LN).  Both of these glycoproteins are critical to neural 
development and have been found to promote cell survival and migration, neurite 
outgrowth and synapse formation (Colognato and Yurchenco, 2000; Perris and 
Perissinotto, 2000; Testaz and Duband, 2001).  In vitro, NSC have increased adhesion 
and migration on both FN and LN compared to collagen types I or IV or tissue culture 
plastic, and this behavior was mediated by β1 integrins present on the NSC (Tate et al., 
2004).  Thus, FN and LN can provide both a physical support and initiate appropriate cell 
signaling to improve survival and integration of donor cells in the injured brain.  
Moreover, the use of an appropriate thermally-reversible protein or polymer, such as 
collagen type I (CnI), allows for minimally invasive delivery of a construct which forms 
a three-dimensional gel in situ.  We have previously shown that delivering NSC within a 
FN/CnI scaffold improved donor cell migration and survival at 3 weeks post-transplant 
(Tate et al., 2002).  In the current study, we delivered NSC within a tissue engineered 
construct containing either FN/CnI or LN/CnI following controlled cortical impact (CCI) 
injury to assess the effects on both NSC function and cognitive behavior of treated 
animals.   
 
Methods 
Neural Stem Cell Isolation and Culture 
Primary fetal-derived green fluorescent protein positive (GFP+) NSC were used for this 
study.  Pregnant transgenic B6-TgN(β-act-EGFP)osbY01 mice (C57BL6 background) 
were sacrificed by cervical dislocation, and embryos were isolated at gestational day 14.5 
by Caesarian section.  The skull layer was removed, allowing parasagittal cuts to be made 
in each hemisphere exposing the germinal layer.  The ganglionic eminence of the 
germinal zone was then separated from the underlying tissue and mechanically 
dissociated into a single cell solution in Hank’s balanced salt solution.  Cells were 
cultured as spheres in media consisting of Dulbecco's modified eagle medium: nutrient 
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mixture F-12 (D-MEM/F12, 1:1; Invitrogen, Carlsbad, CA) containing insulin (25 
µg/ml), transferrin (100 µg/ml), putrescine (60 µM), sodium selenite (30 nM), 
progesterone (20 nM), and glucose (0.3%).  Human recombinant basic fibroblast growth 
factor (bFGF; 20 ng/ml; PeproTech, Rocky Hill, NJ) was added to the media every 2-3 
days to keep the cells proliferating and clustered as neurospheres.  Cells were passaged 
every 7-10 days, as dictated by increases in cell density.  All cell culture reagents from 
Sigma-Aldrich (St. Louis, MO) unless specified otherwise.  Experiments were performed 
using NSC at passage 3, and a total of 10 different flasks were used (from 5 different 
harvests).   No correlation was detected between the flask used and the numbers of 






































Figure 2.1: Correlation of donor cell survival with the flask of NSC used 
Ten different flasks containing NSC were used throughout these experiments.  Based on 
r-values close to 0 (│r│< 0.2), we determine there was not a correlation between the 
















































r = +0.05 
r = ─0.19 
r = ─0.12 
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Rheology Assessment of Collagen I Scaffolds 
Rheological measurements were made to verify that the CnI-based scaffolds used in this 
study were gelling prior to reaching physiologic temperature.  Scaffolds investigated were 
FN/CnI (final concentrations of 100 µg/ml and 1 mg/ml for FN (Invitrogen) and CnI (BD 
Sciences, Bedford, MA), respectively) and LN/CnI (final concentrations of 100 µg/ml and 
1 mg/ml for LN (Sigma-Aldrich) and CnI, respectively).   Samples (n=2 per scaffold) were 
analyzed on a Bohlin CVO rheometer (Bohlin, East Brunswick, NJ) using a parallel plate 
configuration.  A temperature sweep from 15-45ºC (0.5º/sec) was performed at a constant 
frequency (0.045 Hz) and shear stress (0.221 Pa).  Storage (G′) and loss (G″) moduli, and 
strain (γ) were plotted with respect to temperature to determine the characteristic 
temperature at which the solution transitions to form a gel (gelation temperature).    
 
Controlled Cortical Impact Injury 
Adult male C57BL6 mice (7-10 weeks old; Jackson Laboratory, Bar Harbor, MN) were 
anesthetized with 3% isoflurane and placed in a stereotaxic frame, where anesthesia was 
maintained (via gas mask) with 1-2% isoflurane.  After exposing the skull, a 4 mm 
craniectomy was performed over the left fronto-parietal cortex, with the center at 2 mm 
posterior to bregma and 2 mm lateral to the midline.  The CCI was produced with a 3 mm 
diameter pneumatically-operated metal impactor which entered the brain at a velocity of 
6.0 m/sec.  The impact to the brain occurred at a depth of 1.0 mm below the dura matter 
layer and the impactor remained in the brain for 150 msec.  The impactor rod was angled 
15° to the vertical to be perpendicular to the tangential plane of the brain curvature at the 
impact surface.  A linear variable displacement transducer connected to the impactor 
recorded velocity and duration to verify the consistency of the injuries.  After the CCI, 
the incision was sutured and animals were placed on warm pads for recovery.  Sham 
injury surgeries consisted of anesthesia, skull exposure, craniectomy, and suturing.  All 
mice were housed in a temperature-controlled environment with a 12:12-hr light-dark 
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cycle with food and water available ad libitum.  All procedures conformed to guidelines 
set forth in the Guide for the Care and Use of Laboratory Animals and were approved by 
the Emory University Institutional Animal Care and Use Committee.  
 
Transplantation Surgery 
Transplant surgeries were performed 7 days after the CCI injury, because initial cell 
death mechanisms have subsided enough to provide a relatively stable environment and 
cavity formation (Hovda et al., 1995).  All animals were re-anesthetized with 3% 
isoflurane and placed in a stereotaxic frame, where anesthesia was maintained (via gas 
mask) with 1-2% isoflurane.  The previous incision was cut to expose the location of the 
impact.  Transplants were delivered into the injury penumbra by placing a 10 µl syringe 
with 27-gauge needle (Hamilton, Reno, NV) in the center of 4 mm circle formed by the 
craniectomy, and 1.1 mm below the dura matter layer (thus 0.1 mm below the initial 
impact depth).  All transplant injections (7 µl) were given at a constant rate over a 10-
minute period using a syringe pump (Thermo Electron, Waltham, MA).  After the 
injection, the needle was left in the brain for 5 minutes and removed slowly to minimize 
back flow through the needle track.  Following this, the incision was sutured and animals 
placed on warm pads for recovery.  Surgeries for the animals that had received sham 
injuries included the anesthesia, re-opening of the incision, and suturing.   
 
Transplants of NSC Only  
Green fluorescent protein positive NSC, injected at a density of ~30,000 cells/µL, were 
used in the transplant to easily distinguish between host and donor cells during 
histological analysis.  Cell only transplants were at a 1:1 ratio of NSC to media (without 
bFGF).  Vehicle transplants contained media (without bFGF) to control for the effects of 
the media components. 
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Transplants of NSC within ECM-based Scaffold 
In an effort to enhance the presentation and binding of FN or LN to the donor NSC, these 
proteins were immobilized via binding to CnI.  Cells with scaffold injections were at a 
1:1 ratio of NSC to the FN/CnI or LN/CnI mixture to yield final concentrations of 100 
µg/ml and 1 mg/ml for FN or LN and CnI, respectively.  Scaffold only injections 
contained 1:1 media (without bFGF) to FN-CnI mix or LN-CnI mix. 
 
Cognitive Behavior Testing 
The Morris water maze (MWM) task was used to assess spatial learning 
performance (Fox et al., 1998; Morris, 1984).  The MWM apparatus consisted of a white, 
circular tank (diameter = 1 m) filled with opaque water (20±1°C; nontoxic white tempura 
paint) to a depth of 64 cm (23 cm from the top of the tank).  A platform was submerged 
to a depth of 1 cm and placed 28 cm from the wall of the pool in the center of the 
northeast quadrant.  The position of the platform remained constant throughout the study.  
Each animal was given 2 trials per day with a 30 minute inter-trial interval for up to 12 
consecutive days.  At the start of each trial, the mouse was placed in the pool (facing the 
pool wall) at one of four randomly determined starting positions (“N, S, E, W”).  Each 
mouse was allowed to swim freely in the pool until it found the hidden platform or until 
60 seconds had elapsed.  If the mouse did not find the platform in 60 seconds, he was 
manually guided to the platform, where mice remained for 15 seconds before being 
removed from the pool.  A probe-trial using a visible platform to assess visuomotor 
abilities was conducted following the last MWM trial.  A video tracking system (San 
Diego Instruments, San Diego, CA) was utilized to assess the latency to the platform.  
Two criteria were used to exclude mice from analysis: 1- mice that did not find the visual 
platform in under 55 seconds (to account for visual, motor, or motivation aspects of 
locating the platform), and 2- mice that did not have a single GFP+ cell in their brains at 8 
weeks post-transplant (to control for technical problems at the time of transplantation).  
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The following groups were compared, where the n-value denotes number of animals in 
each group that passed the two criteria listed above:  1- injured with NSC in media (n=5), 
2- injured with NSC plus LN/CnI construct (n=5), 3- injured with NSC plus FN/CnI 
construct (n=4), 4- sham (n=10), 5- injured without treatment (n=10), 6- injured with 
media only (n=5), 7- injured with LN/CnI scaffold only (n=3), and 8- injured with 
FN/CnI scaffold only (n=6).    
 
Histology 
Mice were sacrificed for analysis at the following times post-transplant: 1 week (n=6 per 
treatment group), 3 weeks (n=7-8 per treatment group), and 8 weeks (n=8-10 per 
treatment group).  Mice were re-anesthetized with an intraperitoneal injection of 
pentobarbital (80mg/kg), then perfused with 0.1M phosphate buffered saline (PBS), 
followed by 4% paraformaldehyde.  The brains were harvested, immersed overnight in 
4% paraformaldehyde at 4°C, then cryoprotected with 30% sucrose.  The brains were 
then embedded in optimal cutting temperature (OCT) medium (Sakura, Torrence, CA), 
frozen, and stored at -80°C.  A cryostat (Richard-Allan Scientific, Kalamazoo, MI) was 
utilized to serially section the brain into 10 µm thick coronal sections mounted onto 
gelatin-coated slides.    
 
Assessment of Cell Survival and Migration 
The number of surviving donor cells was estimated by quantifying GFP+ cells found in 
the brains.  We first confirmed that the constitutive fluorescence expression matched 
what was labeled using an antibody to GFP (1:500, A11122, Invitrogen) for each of the 
three time points examined (data not shown).  Thus, we were able to count cells in 
unstained tissue.  The optical fractionator method (Gundersen, 1986; Sterio, 1984) was 
utilized to estimate the number of GFP+ cells by counting the entire area of interest for 
40-80 sections at 40 µm increments per brain.  For evaluation of migration, assessments 
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about the anatomical location of the cells and their radial dispersion from the initial 
cluster/clump of transplanted cells were noted.   
 
Qualitative Assessment of Phenotype and Proliferation  
Immunohistochemical analyses were employed to identify phenotypic markers on donor 
cells, and to identify if donor cells were undergoing proliferation at the time of sacrifice 
(n=2 per treatment group per time point; stained sections spaced 160 or 320 µm apart).  
Briefly, sections were rinsed in PBS, and then blotted and permeabilized in 20% goat 
serum and 0.5% tritonX-100 in PBS for 2 hr at room temperature, followed by 1 hr at 
4°C.  Sections were then incubated overnight at 4°C with one the following antibodies 
from Chemicon (Temecula, CA) unless noted otherwise: nestin (marker of neural 
progenitor cells; MAB377, 1:100), Sox-1 (marker of neural progenitor cells; AB5768, 
1:250), glial fibrillary acidic protein (GFAP; marker of reactive astrocytes; MAP360, 
1:400), β-tubulin III (marker of immature neurons; PRB-435P, 1:2000; Covance, 
Berkeley, CA), NeuN (nucleic marker of neurons; MAB377, 1:100), neuron-glial antigen 
2 (NG2; marker of oligodendrocyte progenitor cells; AB5320, 1:100), platelet-derived 
growth factor (PDGF) receptor α (marker of oligodendrocyte progenitor cells; CBL 
1366, 1:50), O4 (marker of immature oligodendrocytes; MAB345, 1:100), 2′,3′-cyclic 
nucleotide 3′-phosphodiesterase (CNPase; marker of oligodendrocytes; MAB326, 1:100), 
or phospho-histone H3 (mitosis marker; #06-570, 1:100; Upstate, Charlottesville, VA).  
Following rinsing in PBS, sections were incubated with the appropriate species secondary 
conjugated to Alexa fluorophore 568 (in the red spectrum; Invitrogen) for 1 hour at room 
temperature.  The percent of cells expressing specific phenotypic markers or H3 






A general linear model ANOVA, followed by Tukey’s pairwise comparisons (Minitab, 
State College, PA) was used to compare the following groups for each time point: 1- 
injured with NSC in media (“NSC only”), 2- injured with NSC plus LN/CnI construct 
(“NSC+LN/CnI”), 3- injured with NSC plus FN/CnI construct (“NSC+FN/CnI”), 4- 
sham (for behavior study only), 5- injured without treatment (for behavior study only), 6- 
injured with media only (for behavior study only), 7- injured with LN/CnI scaffold only 
(for behavior study only), and 8- injured with FN/CnI scaffold only (for behavior study 
only).  An alpha value of 0.05 was used to assess if the means were significantly 
different.  Data are reported in the text as mean ± SD. 
 
Results 
Using collagen I scaffolds allows for minimally invasive delivery 
Collagen I is thermally reversible, thus becomes more viscous with increasing 
temperature (at constant pH).  Mixing bioactive matrix proteins with CnI enables 
minimally invasive delivery of a scaffold support for donor cells.  The gelation 
temperature was assessed for both the FN/CnI and LN/CnI scaffolds to verify that a gel 
formed after injection, but prior to reaching physiologic temperature.  Figure 2.2 shows 
the rheological behavior as a function of temperature for the two scaffolds.  The 
transition from a liquid to a gel is marked by the rapid increase in both the storage (G′) 
and loss (G″) moduli (Kobayashi et al., 1999).  In addition, the strain (γ) rises slightly 
followed by a sudden drop, which is another hallmark of gelation (Takeuchi et al., 2003).   
When FN is bound to CnI to yield final concentrations of 100 µg/ml and 1 mg/ml, 
respectively, the mixture forms a gel at 27.8±1.0ºC (Figure 2.2-top).  When LN is bound 
to CnI to yield final concentrations of 100 µg/ml and 1 mg/ml, respectively, the mixture 
forms a gel at 34.1±0.9 ºC (Figure 2.2-bottom).  The temperature of a mouse brain under 
isoflurane anesthesia is 34.8±1.6°C (unpublished observations), thus, the rheology data 
 30
confirms that both the FN/CnI and LN/CnI scaffolds used in this study remained as a 
liquid when kept cool prior to transplantation, and formed a gel upon approaching 
physiologic temperature.  Consequently, binding FN or LN to CnI allows for minimally 
invasive delivery of cells within a three-dimensional construct into the irregularly-shaped 









































Figure 2.2: Gelation curve of scaffolds used to deliver NSC   
Plot of storage (G′) and loss (G″) moduli and strain (γ) versus temperature, showing that 
the gelation of the FN/CnI mixture (top) occurs at 27.8±1.0ºC, and the gelation of the 
Sharp drop in γ 
Inflection point for G″  
Inflection point for G′  
Sharp drop in γ 
Inflection point for G″  
Inflection point for G′  
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LN/CnI mixture (bottom) occurs at 34.1±0.9 ºC. Thus, both scaffolds transition from a 
viscous liquid to a soft gel upon reaching body temperature.   
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Mice treated with tissue engineered construct containing laminin have improved 
cognitive function 
Injured mice performed significantly worse than uninjured sham animals throughout the 
MWM task which began at 5 weeks post-transplant (p<0.005).  By the end of the testing 
period (days 11-12), mice that were treated with NSC+LN/CnI showed significant 
improvement compared to untreated animals (p=0.03).  An intermediate treatment effect 
was observed for mice that were treated with NSC only or NSC+FN/CnI, as these were 
not significantly different from either injured or sham groups.  Furthermore, the recovery 
for the group treated with NSC+LN/CnI is due to the combination of the NSC with the 
LN-based construct, as the LN/CnI only treatment was significantly worse than both 
sham (p=0.01) and NSC+LN/CnI (p=0.001) groups by the end of the testing period.  





















Figure 2.3: Morris water maze 
Morris water maze testing was conducted at 5 weeks post-transplant.   By the end of the 
testing period (days 11-12), injured animals were significantly worse than uninjured 
shams.  While all the treatment groups containing cells seemed to improve performance 
on this spatial learning task, only the mice treated with NSC in the LN-based scaffold 
were significantly better than untreated animals.  *p<0.01 vs. SHAM, §p=0.03 vs. 
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Cells delivered in tissue engineered constructs have enhanced survival 
Cell counts of surviving GFP+ cells (Figure 2.4) revealed that at 1 week post-transplant 
only 2-3% of the donor cells survived, independent of initial delivery conditions.  These 
low survival rates are consistent with other transplant work in the injured or diseased 
brain (Barker et al., 1996; Lindvall, 2003; Saporta et al., 1999).   By 3 weeks post-
transplant, there was a slight drop in surviving cells for all the groups (again no 
difference among treatments).  However, by 8 weeks post-transplant, cells delivered 
within the FN-based scaffold showed improvement in survival (1,530±220 GFP+ cells) 
compared to NSC transplants in media alone (550±440 GFP+ cells, p=0.06), and cells 
delivered within the LN-based scaffold (2,520±690 GFP+ cells) showed significantly 
improved survival compared to those transplanted in media alone (p=0.005).  Thus, the 
delivery conditions used in this study did not protect cells from the initial drop in 
















Figure 2.4: Survival of GFP+ donor cells  
By 8 weeks post-transplant, NSC seeded in the FN-based scaffold had better survival 
than NSC transplanted alone and NSC seeded in the LN-based scaffold seemed to have 
survival than cells delivered within the FN-based scaffold and had significantly better 
survival than NSC transplanted alone. *p=0.005 (NSC only vs. NSC+LN/CnI), §p=0.06 



























Phenotype, proliferation, and migration are consistent among treatment groups 
The phenotype of the transplanted cells was investigated by probing for the following 
markers: nestin and Sox-1 (neural progenitor cells), GFAP (reactive astrocytes), β-tubulin 
III (immature neurons), NeuN (nucleic marker of neurons), NG2 and PDGF receptor-α 
(oligodendrocyte progenitor cells), O4 (immature oligodendrocytes), CNPase 
(oligodendrocytes).  Of the brain sections assessed, no GFP+ cells were found to double 
label for nestin, Sox-1, β-tubulin III, NeuN, PDGF receptor-α, O4, or CNPase.  
Regardless of treatment conditions or time post-transplant, a small subset (3-7%) of 
donor cells were found to be either GFAP+ or NG2+, indicating a fraction of the NSC 
differentiated into glial phenotypes (data not shown).   As far as donor cell proliferation, 
none of the GFP+ cells were found to be positive for the mitosis marker H3, indicating 
cells were likely not undergoing proliferation at 1, 3, or 8 weeks post-transplant (data not 
shown).  This does not rule out the possibility that proliferation occurred at other time 
points.  However, given the cell survival data, it is not likely that the NSC were 
proliferating after transplantation. 
 
Analyzing the profiles of the GFP+ cells with respect anatomical location and degree of 
dispersion, no differences in migration were observed between treatment groups (Figure 
2.5).  At 1 and 3 weeks post-transplant, GFP+ cells were found either bordering the cavity 
or in the tissue immediately adjacent to the cavity.  By 8 weeks, cells were found 
distributed within the hippocampus tissue for all treatment groups, indicating surviving 
cells migrated to this slightly deeper structure.  One notable difference was that GFP+ 
cells delivered within the FN/CnI scaffold were more clustered together at 1 and 3 weeks 
post-transplant than cells delivered in media or the LN/CnI scaffold.  This is likely due to 
the fact that the FN/CnI scaffold forms a gel at 27.8±1.0ºC, which is well below 
physiologic temperature.  However, the LN/CnI scaffold gels near physiologic 
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temperature, thus may not have completely gelled immediately after injection, allowing 






























Figure 2.5: Migration profile of GFP+ donor cells  
Representative micrographs are shown of the GFP+ cells in the three treatment conditions 
at 1, 3 and 8 weeks post-transplant. At 1 and 3 weeks, cells are found clustered (or in a 
large clump in the case of delivery with FN/CnI) either lining the injury cavity (Cv) or in 
the tissue immediately adjacent.  By 8 weeks, remaining GFP+ cells are found distributed 
within the hippocampus (Hp).  No differences in anatomical location or radial migration 





















We have demonstrated that delivering NSC within specific ECM protein-based scaffolds 
improves donor cell survival and behavioral recovery.  When NSC were transplanted into 
the injury cavity at 7 days post-injury, the initial donor cell survival was poor (2-3% cells 
surviving by 1 week post-transplant), regardless of transplant conditions.  It is possible 
that for all treatment groups, the early drop in cell numbers was caused by the initial 
delivery conditions (i.e. shear stress from passing through the needle), the cytotoxic 
environment of the injured tissue, or an immune response to the donor cells.  The fact that 
this lack of initial survival is observed for multiple cell transplantation paradigms 
necessitates further investigation into the mechanisms governing initial cell death.  
Interestingly, the use of an appropriate ECM protein based scaffold seems to affect the 
cell death rate of the donor cells that do survive the initial stress of the delivery.  Our 
previous work showed that transplanting NSC within a FN/CnI-based scaffold had 
improved survival by 3 weeks post-transplant, and in this study, NSC transplanted within 
a FN/CnI or LN/CnI scaffold had improved survival by 8 weeks.    
 
One of the attractive features of cell transplantation therapy is the ability to provide a 
treatment with a single, minimally-invasive procedure, that can be sustained in the brain 
tissue and evolve with the dynamic environment.  Thus, enhancing later phase survival is 
important to maintain the presence of these donor cells throughout the recovery period.   
Since the scaffolds used in this study are likely not present by 8 (or even 3) weeks post-
transplant, it is remarkable that the acute transplant conditions have such a profound 
effect on non-acute graft survival.  There are a number of potential explanations for this 
later phase difference in cell survival, relating to how the scaffold affects initial donor 
cell behavior.  Delivering NSC has the potential to provide a heterogeneous population of 
cells to the injured brain, but it is likely that the majority of the cells are a common 
phenotype since they are exposed to similar extracellular cues.  It is possible that the 
 41
microenvironment of the ECM-based scaffold selects for more robust cell types.  In 
addition, since both FN and LN are involved in neural development and are found in 
increased levels following brain injury, these proteins may be affecting the host cells, 
subsequently creating a more favorable environment for surviving donor cells.    
 
Incorporating the thermally reversible protein CnI into our tissue engineered construct 
allowed for minimally-invasive delivery of cells, while providing a three-dimensional 
support scaffold in situ.  This system enables the construct to conform to an irregularly-
shaped injury cavity and still provide physical support to donor cells.  We chose to 
incorporate CnI into the scaffold based on the gelation properties of this ECM protein; 
which provided a structural for the FN or LN and subsequently the NSC.  Because we 
were focusing on improving the behavior of the transplanted NSC, and CnI did not 
enhance adhesion or migration of these cells in vitro, we focused on the FN or LN as the 
bioactive scaffold components.  However the contribution of CnI cannot be ignored.  
Collagen I hydrogels have been used in vitro to support the proliferation and 
differentiation of neural stem and progenitor cells (Ma, 2004).  Thus, the CnI transplanted 
with the NSC may also provide initial support for the donor cells.   
 
The similarities in migration patterns between treatment groups was unexpected since 
previous studies transplanting NSC within a similar FN/CnI scaffold found enhanced 
migration by 3 weeks post-transplant.  However, the cells from that study were used at 
passage 2 (versus 3), thus may have been more migratory.  In both studies, cells migrate 
to the hippocampus.  It is possible that the presence of the ECM scaffold selects for more 
migratory cells that move to the hippocampus at earlier time points than cells 
transplanted alone, and this occurred between 3 and 8 weeks in the study presented here.  
Notably, we have previously shown that performance on the Morris water maze spatial 
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learning task is correlated with the number of surviving donor cells in the hippocampus 
(Shear et al., 2004); and this was corroborated by the work presented here.   
 
The future use of LN versus FN in transplant paradigms seems more appealing since cells 
delivered in the LN/CnI scaffold had increased survival compared to those delivered in 
the FN/CnI scaffold.  Furthermore, only the group treated with the construct containing 
both NSC and LN was significantly better than the untreated group in a spatial learning 
task.  Further exploration utilizing LN-based scaffolds may continue to improve graft 
survival and integration, and ultimately promote functional recovery.  Our laboratory is 
currently examining cross-linking LN or LN peptides to a thermo-reversible polymer 
(methylcellulose) for use as a scaffold (Stabenfeldt et al., 2006).  This system allows us to 
better control the microenvironment of the donor cells, and will enable advancements 
such as increasing the density of functional LN peptides, altering the scaffold degradation 
rate, or incorporating neurotrophic growth factors in order to appropriately support and 
direct NSC.   
 
In summary, we have utilized tissue engineering strategies to improve survival of grafted 
cells, which resulted in cognitive recovery.  Inspired by the success of fetal tissue 
transplants, we engineered a construct containing NSC supported physically and 
chemically by ECM proteins.  This design can be exploited for a number of CNS 
disorders which could also benefit from increased survival of transplanted NSC, 
including spinal cord injury and stroke.  Tissue engineering allows for enhanced control 
over transplanted cells, and will likely prove useful in augmenting cell transplantation 
therapy in the CNS.   
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CHAPTER 3 
FIBRONECTIN AND LAMININ INCREASE IN THE MOUSE BRAIN 
FOLLOWING CONTROLLED CORTICAL IMPACT INJURY 
 
Abstract 
The complex environment of the traumatically injured brain exhibits aspects of inhibition 
and ongoing cell death together with attempts at repair and regeneration.  Elucidating 
these events and exploiting factors involved in endogenous repair and regeneration may 
aid in developing more effective treatments for traumatic brain injury.  Two extracellular 
matrix proteins critical to neural development - fibronectin and laminin - may also play a 
protective or reparative role in the injury response.  While both of these proteins have 
been found to increase following human brain injury, the presence of these proteins has 
not been studied in a clinically-relevant animal model of blunt head trauma.  In this 
study, we examined the spatiotemporal profile of both fibronectin and laminin in the 
mouse brain following controlled cortical impact injury.  Fibronectin and laminin 
reactivity was localized to the injury penumbra up to 14 days post-injury and was 
significantly higher than uninjured controls at 3 days post-injury.  Upon examining the 
spatial relationship of fibronectin and laminin to support cells, we found 
macrophages/activated microglia prominently present in the fibronectin-rich tissue, 
consistent with a role for fibronectin in facilitating debris clearing.  Furthermore, reactive 
astrocyte processes were found sheathing laminin positive vasculature, suggesting that 
laminin may play a role in repairing the blood-brain barrier.  These and other 






Following traumatic brain injury (TBI) there is a dynamic interplay among factors 
promoting repair and regeneration in competition with factors inhibiting such functions.  
It is important to understand mechanisms across this continuum to develop treatments 
that enhance cell survival and regeneration.  Many different extracellular matrix (ECM) 
proteins have been found to increase following brain injury.  While much attention has 
been devoted to identifying ECM proteins that inhibit regeneration, particularly 
chondroitin sulphate proteoglycans (for review, see Properzi et al., 2003), there are ECM 
proteins in the injured brain that may be beneficial to injured and regenerating tissue.  
Two ECM proteins of particular interest are fibronectin (FN) and laminin (LN).  Human 
studies have shown an increase in both FN (Liu and Sturner, 1988) and LN (Hausmann 
and Betz, 2000) following TBI.  An increase in FN has also been seen in various 
experimental brain insults, including penetrating stab wound (Egan and Vijayan, 1991; 
Mizutani and Kimura, 1987), cortical cold injury (Nag et al., 1997; Suzuki and Choi, 
1990), and kainic acid lesion (Hertel et al., 2000), while LN has been found in increased 
levels after cortical cold injury (Kakinuma et al., 1998; Suzuki and Choi, 1990) and 
penetrating stab wound (Szabo and Kalman, 2004).  However, neither of these proteins 
has been evaluated using a model of blunt trauma, the most common type of head injury 
in humans (Langlios, 2004).  Because of the physical and chemical complexities 
associated with blunt trauma, it is important to evaluate the early injury response in 
appropriate animal models.  Two well-studied models of TBI in rodents are the fluid 
percussion and controlled cortical impact (CCI) injury, both of which mimic many 
pathological aspects of human closed head injury, such as cell death in multiple locations 
in the brain and prolonged cognitive and motor deficits (Dixon et al., 1991; Fox et al., 
1998).  In this study, we examined the spatiotemporal profile of both FN and LN 




Controlled Cortical Impact Injury 
Adult male C57BL6 mice (6-10 weeks, Jackson Laboratory, Bar Harbor, MN) were 
anesthetized with an intraperitoneal injection of ketamine (62 mg/kg) and xylazine (50 
mg/kg) and placed in a stereotaxic frame.  After exposing the skull, a 4 mm craniectomy 
was performed over the left fronto-parietal cortex, with the center at 1.0 mm posterior to 
bregma and 1.5 mm lateral to the midline.  CCI was produced with a 3 mm 
pneumatically-operated metal impactor which enters the brain at a velocity of 6.0 m/sec.  
The impact to the brain occurred at a depth of 1.0 mm below the dura matter layer and 
the impactor remained in the brain for 150 msec.  The impactor rod was angled 15° to the 
vertical to be perpendicular to the tangential plane of the brain curvature at the impact 
surface.  A linear variable displacement transducer connected to the impactor recorded 
velocity and duration to verify the consistency of the injuries.  After the CCI injury, the 
incision was sutured and animals were placed on warm pads for recovery.  Sham injury 
surgeries consisted of anesthesia injection, skull exposure, craniectomy, and suturing.  
All mice were housed in a temperature-controlled environment with a 12:12-hr light-dark 
cycle with food and water available ad libitum.  All procedures conformed to guidelines 
set forth in the Guide for the Care and Use of Laboratory Animals and were approved by 
the Georgia Institute of Technology Institutional Animal Care and Use Committee. 
 
Histology 
Mice were sacrificed for analysis at the following post-injury time points: 1 day (n=5), 3 
days (n=5), 7 days (n=4), 14 days (n=2), and 7 weeks (n=2).  In addition, sham 
(uninjured; n=3) brains that underwent all surgical procedures excluding the impact were 
also immunostained to establish baseline levels of ECM expression.  Mice were re-
anesthetized with an intraperitoneal injection of ketamine (124 mg/kg) and xylazine (100 
mg/kg), then perfused with 0.1M phosphate buffered saline (PBS), followed by 4% 
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paraformaldehyde.  The brains were harvested, immersed overnight in 4% 
paraformaldehyde at 4°C, then cryoprotected with 30% sucrose. The brains were then 
embedded in optimal cutting temperature (OCT) medium (Sakura, Torrence, CA), frozen, 
and stored at -80°C.  A cryostat (Richard-Allan Scientific, Kalamazoo, MI) was utilized 
to serially section the brain into 16 µm thick cut coronal sections.    
 
Immunohistochemistry was performed to detect FN, LN and glial fibrillary acidic protein 
(GFAP; a marker of reactive astrocytes).  Briefly, sections were rinsed in PBS, and then 
blotted and permeabilized in 8% goat serum and 0.1% tritonX-100 in PBS for 1 hr at 
room temperature.  Sections were then incubated overnight at 4°C with the following 
antibodies (Chemicon, Temecula, CA) for FN (AB2033, 1:50), LN (AB2034, 1:100) 
and/or GFAP (MAB360, 1:400).  Following rinsing in PBS, sections were incubated in 
the corresponding fluorescent conjugated secondary antibodies (Sigma-Aldrich, St. 
Louis, MO, and Jackson ImmunoResearch, West Grove, PA) for 2 hours at room 
temperature.  To identify macrophages and reactive microglia, fluorescent-conjugated 
isolectin IB4 was used for its ability to bind carbohydrates on these phagocytic cells, as 
previously described (Maddox et al., 1982; Pennell et al., 1994).  The conjugated 
isolectin IB4 (1:100; Molecular Probes, Eugene, OR) was added just as the primary 
antibody described above.  Note that for double staining, antibodies were applied 
simultaneously.  Fluorescent microscopy was used to visualize staining.   
 
Quantification and Statistics 
The areas of FN+ and LN+ tissue were quantified separately using Image Pro® software 
(Media Cybernetics, Silver Spring, MD).  Briefly, the total area of positively stained 
tissue above a threshold intensity (set by the highest intensity for that brain’s 
immunohistochemical negative controls) was determined for each section.  The total area 
of ECM+ tissue per section was then averaged for a given brain and then for all the brains 
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from each time point.  These areas were compared to the amount of positive staining in 
uninjured control brains using a general linear model ANOVA (Minitab, State College, 
PA), followed by Tukey’s pairwise comparisons.  An alpha value of 0.05 was used to 
assess if means were significantly different.   
 
Results 
Spatiotemporal Profile of Fibronectin and Laminin 
Fluorescent microscopy revealed that both FN and LN were consistently present in brain 
tissue adjacent to the injury site up to 14 days post-CCI injury, and there was negligible 
immunolabeling for FN or LN in other areas of the brain, consistent with previous 
findings that normal adult brain tissue contains low levels of these ECM proteins (Bellail 
et al., 2004; Maenpaa et al., 1997).  In the injury penumbra, the FN+ tissue was 
distributed throughout the extracellular space in a seemingly random arrangement 
(Figure 3.1–A).  LN+ tissue was along vasculature within the injured cortex adjacent to 
the injury site (Figure 3.1–B).  Quantification of the amount of positively stained tissue 
revealed that the amount of both positive tissue was significantly higher than uninjured 
sham brains at 3 days post-CCI injury for both FN (p=0.02) and LN (p=0.03) (Figure 

















Figure 3.1: Spatial localization of FN and LN post-injury  
Both FN and LN are distributed around the tissue adjacent to the cavity.  Morphology of 
FN+ tissue (A, green) appeared to be distributed in the extracellular space between neural 
cells, and LN+ tissue (B, red) appears to surround vasculature.  Images are at 3 days post-


















Figure 3.2: Temporal profile of FN+ and LN+ tissue in the injury penumbra 
following CCI injury   
Immunoreactivity of FN and LN was significantly higher than uninjured controls at 3 


































Time post-CCI injury 
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Spatial Proximity of Fibronectin and Laminin to Support Cells 
To determine if support cells were interacting with these ECM proteins in the injured 
tissue, we double labeled for FN and LN with isolectin IB4 to identify macrophages or 
activated microglia and with GFAP antibody to identify reactive astrocytes.  Isolectin+ 
cells exhibiting a rounded morphology (indicative of either macrophages or activated 
microglia) were found bordering the lesion at 3 days and in greater numbers at 7 days 
post-CCI injury, which is a similar pattern to that seen in contused human brains (Holmin 
et al., 1998).  At 3 and 7 days post-CCI injury, the majority of isolectin IB4+ cells could 
be seen in areas of FN-rich tissue adjacent to the site of injury (Figure 3.3-A).  As 
expected, GFAP+ cells were seen bordering the injury site at all time points examined, 
and the intensity and density were maximal at 7 days post-CCI injury.  Up to 7 days post-
CCI injury, many of these GFAP+ cells were found bordering the LN stained areas 
(Figure 3.3-B).   Specifically, the LN+ tissue coincided with microvasculature near the 
injury site, and astrocytic processes appeared to surround the circumference of these LN+ 











Figure 3.3: Co-spatialization of FN and LN with support cells   
A. The majority of macrophages/activated microglia (red) were found in regions of FN+ 
tissue (green); B. Activated astrocytes (green) are often found in proximity to LN+ tissue 
(red).  Note that reactive astrocytes wrap the LN+ vasculature (arrows in B).  Images 





We evaluated the spatiotemporal profile of two ECM proteins, FN and LN, following 
CCI injury.  This was the first analysis of these proteins using a model of blunt TBI.  We 
found both proteins increase in the injury penumbra up to 1 week post-injury, and the 
area of ECM+ tissue was significantly higher than uninjured brains at 3 days post injury.  
In addition, we determined that these proteins correlate spatially with support cells.  
Specifically, FN correlates with macrophages or activated microglia and LN correlates 
with reactive astrocytes.   
 
This spatial proximity of FN and isolectin+ phagocytic cells may result because both 
monocyte-derived macrophages and at least some FN are blood borne, and permeate into 
the injured brain tissue during acute increases in blood-brain barrier (BBB) permeability 
(Giulian et al., 1989; Nag et al., 1997).  Moreover, this could point to a functional 
relationship similar to that seen in cutaneous wound healing, where FN acts as an opsonin 
for phagocytes, thereby aiding in the clearance of dead tissue and debris (Martin et al., 
1988), and accelerating the healing process (Lariviere et al., 2003).  Further investigation 
is warranted to determine if this spatial proximity is strictly due to their common source 
or if there is a functional, and moreover, beneficial relationship.   
 
The correlation of GFAP+ reactive astrocytes with LN+ vessels indicates a role for LN in 
restoring vasculature and the BBB.  Laminin increases also correlate temporally with the 
biphasic opening of the BBB which occurs within the first 6 hours and again at 3 days 
post-injury (Baskaya et al., 1997).  Perhaps astrocytes are secreting LN (Freire et al., 
2004) to temporarily seal breaches in the BBB.  An alternative explanation is that the 
LN+ vasculature corresponds with the reformation of basal laminae during angiogenesis 
(Davis and Senger, 2005; Grant et al., 1990) and the close proximity of reactive 
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astrocytes is due to restoration of the BBB formed by astrocytic end feet (Risau and 
Wolburg, 1990).   
 
In addition to the aforementioned hypothesized functions based on the spatial overlap of 
FN with macrophages/activated microglia and LN with reactive astrocytes, there are 
other plausible mechanisms for these ECM proteins in the injured brain, including 
regenerative and pro-survival roles.  For example, both FN and LN have been shown to 
promote cell migration, neurite extension and synapse formation in the developing brain 
(Bi et al., 2001; Einheber et al., 1996; Tsuru et al., 1996).  Since the injured brain 
recapitulates many aspects of development (e.g., neuro- and gliogenesis, angiogenesis, 
increase in ECM proteins), FN and LN may be aiding in regeneration.  For example FN 
in the extracellular tissue may act as a substrate for the migration of astrocytes and 
microglia to the site of injury.  Since FN and LN are supportive for neurite outgrowth, 
their presence may be an endogenous attempt to compete with inhibitory components of 
found in the extracellular environment.  Or, FN and LN may aid in synapse formation as 
neighboring neurons compensate for the damaged / lost networks.  However, by the time 
regeneration or plasticity are favorable (after the initial volatile spread of injury), the 
expression of these proteins returns to normal.    
 
Another potential reparative mechanism for FN in the injured tissue is decreasing 
apoptosis.  Fibronectin has been shown to be anti-apoptotic for many cell types in vitro 
(Fukai et al., 1998; Zhang et al., 1995), including neurons (Gibson et al., 2005); and 
plasma FN null mice had increased apoptosis following in vivo ischemia (Sakai et al., 
2001).  It has been found in vitro that FN binding to α5β1 integrin increases expression of 
Bcl-2, which subsequently decreases apoptosis (Fukai et al., 1998; Gibson et al., 2005; 
Zhang et al., 1995).  Since the α5β1 integrin is expressed by adult neural cells (King et al., 
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2001; Pinkstaff et al., 1999), FN may aid in salvaging cells in the injury penumbra via 
anti-apoptotic signaling.   
 
In further support of a beneficial role for FN and LN in the injured brain is the 
therapeutic use of these proteins in experimental brain injury.  Functional peptides from 
both FN (Yanaka et al., 1996) and LN (Yanaka et al., 1997) have been shown to reduce 
polymorphic leukocyte accumulation and infarct size and improve neurological outcome 
following cerebral ischemia.  In addition, LN-based hydrogels encouraged cell infiltration 
and angiogenesis and reduced glial scar formation when implanted into a brain cavity 
(Hou et al., 2005).   
 
In summary, this study examined the spatiotemporal profile of FN and LN in the injured 
brain using a clinically relevant model of blunt trauma.  We found that both proteins 
increase in the injury penumbra at acute time points and are spatially associated with 
support cells.  Based on these associations, as well as the roles of FN and LN in neural 
development and other peripheral systems, it is hypothesized that these proteins have 
reparative roles, which are summarized in Figure 3.4 (FN) and Figure 3.5 (LN).  This 
hypothesis needs to be further examined to better understand how these ECM proteins fit 
into the complex, interdependent pathology.  It is important to determine the mechanisms 
of action underlying repair/regeneration as well as inhibition since functional treatments 














Figure 3.4: Potential mechanisms for fibronectin in the injured brain  
This is an overview of possible reparative mechanisms for FN in response to traumatic 
brain injury.  Based on the co-spatialization of FN with macrophages / activated 
microglia and the role of FN in wound healing and tissue repair in the periphery, FN may 
be aiding in phagocytosis of injured tissue.  Based on the information that FN is anti-
apoptotic for various cell types, including neurons, and the fact that adult neural cells 
express integrins for FN indicate a potential role in reducing apoptosis of cells vulnerable 
to secondary cell death.  Finally, based on the critical role of FN in neural development, 
and the observations that the brain attempts to re-develop following injury, FN may be 
promoting migration, neurite outgrowth and synapse formation for regenerating neurons, 
or may be recruiting glial cells, such as microglia and astrocytes, to the site of injury. 
 
Increased FN after TBI
Decrease apoptosis Promote 
opsonization 
Promote cell migration, 


















Figure 3.5: Potential mechanisms for laminin in the injured brain 
This is an overview of possible reparative mechanisms for LN in response to traumatic 
brain injury.  Based on the fact that LN was found in increased amounts around 
vasculature and reactive astrocytes were found wrapping the circumference of these LN+ 
vessels a role for LN in restoring the blood-brain barrier is hypothesized.  Astrocytes may 
secrete LN to temporarily seal gaps in the blood-brain barrier and/or LN may be involved 
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CHAPTER 4 
PLASMA FIBRONECTIN IS NEUROPROTECTIVE FOLLOWING 
TRAUMATIC BRAIN INJURY 
 
Abstract 
Certain extracellular matrix components inhibit neural regeneration in the traumatically 
injured brain.  In the case of the matrix protein fibronectin, traumatic brain injury leads to 
increased levels of plasma-derived fibronectin in the brain tissue.  Using conditional 
plasma fibronectin (pFN) knockout mice, we determined that pFN is neuroprotective 
following traumatic brain injury.  Injured mice deficient in pFN performed significantly 
worse on motor and cognitive tasks, had significantly increased lesion volume and 
apoptotic cell death, and had significantly less phagocytic cells in the injured cortex 
compared to injured mice with normal pFN.  Moreover, intravenous injections of 
fibronectin prior to the injury rescued the neural deficits seen in the pFN deficient mice.  
These results demonstrate that fibronectin is neuroprotective to the injured brain and 
identify a novel target for therapeutic interventions. 
 
Introduction 
Traumatic brain injury (TBI) remains a major health and socioeconomic problem in the 
United States (Langlios, 2004).  Developing effective treatment strategies has been 
difficult due to the complex microenvironment of the traumatically injured brain, where 
processes that promote repair and regeneration (e.g., neurogenesis, angiogenesis) 
compete with mechanisms of secondary damage and inhibition (e.g., excitotoxicity, 
increase in chondroitin sulphate proteoglycans (CSPGs)).  Significant attention has been 
given to the extracellular matrix (ECM) environment in the injured brain, primarily due 
to inhibitory properties of certain ECM proteins (e.g., CSPGs, Nogo) (Properzi et al., 
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2003).  However, other components of the ECM environment, such as fibronectin (FN) 
may aid in repair and support regeneration.  Fibronectin promotes cell migration, neurite 
outgrowth and synapse formation during neural development (Reichardt and Tomaselli, 
1991), but is largely absent in adult brain tissue (Maenpaa et al., 1997).  However, levels 
of FN increase following both clinical (Liu and Sturner, 1988) and experimental (Egan 
and Vijayan, 1991; Hertel et al., 2000; Nag et al., 1997)  TBI.  These FN increases in the 
traumatically injured brain are likely involved in repair since FN plays a reparative role in 
wound healing (Grinnell, 1984), has been shown to be anti-apoptotic for many cells in 
vitro, including neurons (Gibson et al., 2005), and is beneficial following brain ischemia 
(Sakai et al., 2001).    
 
Fibronectin is encoded by a single gene, and alternative splicing generates different 
isoforms.  Two major forms of FN are found in the body: cellular FN, which is produced 
in a variety of cell types and is immobilized in ECM, and plasma FN (pFN) which is 
made by hepatocytes and secreted in soluble form into the blood (Kornblihtt et al., 1985).  
Since the elevated fibronectin levels after TBI are largely due to an increase in blood-
brain barrier (BBB) permeability  and cellular FN is not expressed in wounded tissue 
following ischemic brain injury (Sakai et al., 2001), it is hypothesized that the majority of 
FN found after TBI is plasma borne.  Thus, the use of conditional adult pFN null mice 
allows us to investigate for the first time the role of FN in the traumatically injured brain.  
Plasma FN null mice were compared to wild type (WT) littermates following a moderate 
controlled cortical impact (CCI) injury.  Furthermore, a subset of the pFN null mice 
received intravenous (IV) injections of pFN prior to the injury to determine if differences 
were due specifically to the absence of pFN.  Animals were compared on the basis of 





Plasma Fibronectin Knockout Mice  
Plasma FN null mice (129Sv/C57BL6; breeder pairs generously provided by H.P. 
Erickson and R.O. Hynes) were generated via the Cre-loxP conditional gene knockout 
system as previously described (Sakai et al., 2001).  Briefly, mice containing a floxed (fl; 
loxP-site containing) FN allele were crossed with mice expressing Cre under the control 
of the interferon and polyinosidic-polycytidic acid (pIpC) Mx promoter.  This generates 
mice carrying the null allele (FN(fl/fl)/Mx-Cre+; FN(fl/fl) mice carrying the Mx-Cre 
transgene).  This system has been shown to completely delete the FN gene in the liver 
(Sakai et al., 2001), where pFN production occurs.  The deletion of the FN gene was 
induced in male mice at least 8 weeks old by 3 intraperitoneal injections of 250 µg pIpC 
at 2 day intervals.  Mice were used for experimentation 1 month after the last pIpC 
injection.  Blood samples were taken from all animals to verify the absence of pFN for 
knockout-induced mice using western blot analysis.  Note that FN(fl/fl)/Mx-Cre+ with 
pIpC are referred to as “pFN null” and FN(fl/fl)/Mx-Cre–  littermates with pIpC are 
considered “WT” for these studies.  All mice were housed in a temperature-controlled 
environment with a 12:12-hr light-dark cycle with food and water available ad libitum.  
All procedures conformed to guidelines set forth in the Guide for the Care and Use of 
Laboratory Animals and were approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee.  
 
Genotyping  
All animals used for this study (including breeders) were genotyped to identify the 
presence or absence of the Mx-Cre transgene.  Tissue samples for genetic analysis were 
obtained from the tails of 3-5 week old mice.  DNA was extracted from the tissue using a 
DNeasy® Tissue Kit (Qiagen, Valencia, CA) and quantified using the PicoGreen® 
dsDNA Quantification Kit (Invitrogen, Carlsbad, CA).  DNA was amplified by 
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polymerase chain reaction (PCR) using the primers for Cre forward (5'-
ACTATCCAGCAACATTTGGGCCAG-3') and Cre reverse (5'-
GATCCTGGCAATTTCGGCTATACG-3'); primers for Beta5 forward (5'-
CTACAGCATACCTGCTTCACTGTG-3') and Beta5 reverse (5'-
GCCTTTCTGTGGGTTCCA-3') to use as internal controls (all primers from Invitrogen).  
Amplified DNA samples were run through electrophoresis using a 2% agarose gel 
(Fisher, Hampton, NH) and labeled with ethidium bromide (Kodak, New Haven, CT) for 









Figure 4.1: Agarose gel for electrophoresis of DNA 
Heterozygous FN(fl/fl)/Mx-Cre+/– mice were used for this study, thus DNA samples from 
all animals were genotyped to identify the presence of the Cre transgene (as shown 
above).  All study mice received injections of polyinosidic-polycytidic acid, which 
promotes the transcription of Cre on the Mx promoter, and thus the deletion of FN.  
Complete deletion of the FN gene in the liver occurs in Cre+ mice (“pFN null”), and no 




Cre (~282 bp) 
β5 (~434 bp) 
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Plasma Fibronectin Administration  
Soluble human pFN (Invitrogen) was injected into the bloodstream for a subset of the 
pFN null mice to test if changes in injured pFN null mice are reversed by replacing FN, 
For rodents, physiological concentrations of pFN are 580µg/ml (George et al., 1993) and 
the half-life ranges from 15-30 hours (Gauperaa and Seljelid, 1985; Kiener et al., 1986).  
Thus, to approximate “normal” pFN circulation in the blood, an IV injection (via the tail 
vein) of soluble pFN (~50mg/kg) was given to the mice 6 hours prior to surgery.  Blood 
samples were collected at the time of injury to determine the amount of pFN in 
circulation using western blot analysis.  Plasma FN null mice that received IV injections 
of pFN are referred to as “pFN null + pFN IV”.  
 
Western Blot Analysis 
Blood drawn via the saphenous vein (~50 µl) was spun for 10 minutes at 2,300 cgf to 
separate the plasma from the cellular components, for subsequent western blot analysis.  
Proteins from denatured plasma samples (50 µg of total protein based on micro 
bicinchoninic acid protein analysis) were separated with standard SDS-PAGE, followed 
by protein transfer onto nitrocellulose membranes.  Membranes were incubated in 
blocking buffer (5% nonfat dry milk, 0.1% Tween20, and 0.02% NaN3 in phosphate 
buffered saline (PBS)) overnight at 4°C.  Membranes were then blotted with FN antibody 
(F3648, 1:1000; Sigma-Aldrich, St. Louis, MO) for 1 hour at room temperature, followed 
by rinsing and blotting with an alkaline phosphatase-conjugated secondary antibody 
(1:10,000; Jackson ImmunoResearch, West Grove, PA) for 1 hour at room temperature.  
After the addition of ECF substrate (Amersham, Buckinghamshire, UK), bands were 
detected using a fluorescent image analyzer (Fuji FLA-3000, Stamford, CT).  Band 
intensities were quantified (Adobe Photoshop, Adobe Systems, San Jose, CA) and 
averaged for a each group on a given blot in order to assess the relative amounts of pFN 
in the pFN null and pFN null + pFN IV groups compared to WT animals.   
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Controlled Cortical Impact Injury 
Adult male mice (14-28 weeks old) were anesthetized with 3% isoflurane and secured in a 
stereotaxic frame, where anesthesia was maintained (via gas mask) with 1-2% isoflurane.  
After exposing the skull, a 4 mm craniectomy was performed over the left frontoparietal 
cortex (center at -2.0 mm AP and +2.0 mm ML to bregma).  A pneumatically-operated 
metal impactor (diameter = 3 mm) impacted the brain at a velocity of 6.0 m/sec reaching a 
depth of 1.0 mm below the dura matter layer and remained in the brain for 150 msec.  The 
impactor rod was angled 15° to the vertical to be perpendicular to the tangential plane of 
the brain curvature at the impact surface.  A linear variable displacement transducer 
(Macrosensors, Pennsauken, NJ) connected to the impactor measured velocity and duration 
to verify consistency of the injuries.  After the CCI, the incision was sutured when all 
bleeding had ceased.  Sham injury surgeries (for uninjured controls) consisted of 
anesthesia, scalp incision, craniectomy, and suturing.   
 
Motor Behavior  
The rotarod and beam walk tasks were used as measures of motor ability.  For both tasks, 
mice were given three trials per time point, and the mean value was used in the data 
analysis.  Mice were allowed to rest for at least 30 seconds between trials for both 
training and testing.  Testing occurred at 1 day pre-CCI injury (baseline), at 3 and 7 days 
post-CCI injury, then weekly up to 10 weeks post-CCI injury, except during the period of 
MWM testing.  Note that sham injury groups included uninjured WT (n=11), pFN null 
(n=4), and pFN null + pFN IV mice (n=4).  For analysis purposes, these groups were 




Note that previous studies have indicated that uninjured 129SvEMS mice perform 
significantly worse on the beam walk task compared to uninjured C57BL6 mice (Fox et 
al., 1999).   Thus, a preliminary study was performed to assess the motor ability of the 
mice used in this study which are on a C57BL6x129Sv back-strain by comparing 
uninjured C57BL6x129Sv (FN(fl/fl), Mx/Cre-) mice (n=15) with uninjured C57BL6 mice 
(n=9; Jackson Laboratory, Bar Harbor, MN) on both the rotarod (10 and 20 rpm) and 
beam walk (6 mm) tasks.  In addition, to control for effects of pIpC administration, 
uninjured C57BL6x129Sv (FN(fl/fl), Mx/Cre-) mice that received pIpC injections (n=13) 
were also compared.  Results of this preliminary study are shown in Figure 4.2, revealing 
no significant differences between the different strains of mice on the 10 rpm rotarod task 
(p>0.9) or the 6 mm beam walk task (p>0.2).  However, the uninjured C57BL6x129Sv 
(FN(fl/fl), Mx/Cre-) mice were significantly better than uninjured C57BL6 mice on the 20 
rpm rotarod task (p<0.001).  As for the effects of the pIpC drug administration used in 
this study, there were no differences between mice that received pIpC injections 
compared to the same strain of mice that did not receive the pIpC injections for both of 
the rotarod tasks and the beam walk task.  
 
Rotarod 
A rotarod apparatus with automatic fall detection (Columbus Instruments, Columbus, OH) 
was used to assess gross motor function, specifically hind limb control and grip strength 
(Fox et al., 1998).  All mice were trained over four consecutive days prior to baseline 
assessments.  During training, mice were placed on the rod rotating at either 5 or 10 rpm 
and removed from the rod at 60 seconds if they have not fallen prior to this time.  Training 
includes four trials per day at 10 rpm, and an additional two trials at 5 rpm speed prior to 
beginning the 10 rpm trials on the first day (to acclimate the mice to the rotarod).  For 
testing, mice were placed on a spindle rotating at constant speed of 20 rpm (for 3 trials).  
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Latency to fall (height = 25 cm) was recorded, and if the animal did not fall within 60 
seconds, it was removed from the rod.   
 
Beam Walk 
A narrow balance beam was employed to measure fine motor coordination (Fox et al., 
1998).  Mice were trained 1 day prior to surgery, and testing for baseline levels began 
after all animals had been trained.  The animals were placed at a start point near the 
suspended end of a narrow beam (width of first 50 cm = 12 mm, width of second 50 cm = 
6 mm, height from padded surface = 25 cm) and allowed to traverse the beam 100 cm 
into a darkened goal box.  Since injury to the left frontoparietal cortex is involved in 
motor control for the right hindlimb, the outcome measure was the percentage of the total 
right hindlimb steps that are foot faults (when the paw slips 5 mm or more below the 
beam surface).   
 
Cognitive Behavior – Morris Water Maze 
A MWM task was used to assess spatial learning performance at week 6 post-CCI injury 
(Morris, 1984).  The MWM apparatus consisted of a white, circular tank (diameter = 1 m) 
filled with opaque water (20±1°C; nontoxic white tempura paint) to a depth of 52 cm (23 
cm from the top of the tank).  A platform was submerged to a depth of 1 cm and placed 
30 cm from the wall of the pool in the center of the northeast quadrant.  The position of 
the platform remained constant throughout the study.  Each animal was given 2 trials per 
day with a 30 minute inter-trial interval for 12 consecutive days.  At the start of each trial, 
the mouse was placed in the pool (facing the pool wall) at one of four randomly 
determined starting positions (“N, S, E, W”).  Over the course of 4 trials (2 days) all 
positions were tested, thus data are reported as the average latency to platform over these 
4 trials.  Each mouse was allowed to swim freely in the pool until it found the hidden 
platform or until 60 seconds had elapsed, and a video tracking system (San Diego 
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Instruments, San Diego, CA) was utilized to measure the latency to the platform.  If a 
mouse did not find the platform in 60 seconds, it was manually guided to the platform, 
where mice were allowed to rest for 15 seconds before being removed from the pool.  A 
probe-trial using a visible platform to assess visuomotor abilities was conducted 
following the last MWM trial, and mice that did not find the visible platform in less than 
55 seconds were removed from the analysis.  As stated above, sham injury groups from 
WT (n=6), pFN null (n=3), and pFN null + pFN IV mice (n=4) were combined for 
analysis purposes because there was no significant difference between them (p>0.05).  
 
Note that previous studies have indicated that 129SvEMS do not learn to find the hidden 
platform in the MWM  maze task (Fox et al., 1999).  Thus, a preliminary study was 
performed to assess the spatial learning ability of the mice used in this study, which are 
on a C57BL6x129Sv back-strain, by comparing uninjured C57BL6x129Sv (FN(fl/fl), 
Mx/Cre-) mice (n=15) with uninjured C57BL6 mice (n=9) on the MWM.  In addition, to 
control for effects of pIpC administration, uninjured C57BL6x129Sv (FN(fl/fl), Mx/Cre-) 
mice that received pIpC injections (n=13) were also compared.  Results of this 
preliminary study are shown in Figure 4.2, indicating that all groups tested significantly 
decrease their latency to find the hidden platform by testing days 5-6 (p<0.05 versus days 
1-2), and there are no differences between the groups tested at any testing day (p>0.2).  
Thus, we can conclude there was not a significant contribution of either the back-strain or 




























Figure 4.2: Behavioral comparison of C57BL6x129Sv mice with and without pIpC 
and C57BL6 mice 
Preliminary behavior studies revealed no effect of giving the pIpC drug to the 
C57BL6x129Sv (FN(fl/fl), Mx/Cre-) mice for any of the behavior tasks examined.  Also, 
there were no differences between uninjured C57BL6x129Sv (FN(fl/fl), Mx/Cre-) mice 
(with or without pIpC) and uninjured C57BL6 mice on the 10 rpm rotarod, the 6 mm 
beam walk task, or the MWM task.  However, on the 20 rpm rotarod task, the uninjured 
C57BL6x129Sv (FN(fl/fl), Mx/Cre-) mice both with and without pIpC were significantly 
better than uninjured C57BL6 mice (*p<0.001).  Mean ± SEM; #p<0.05 versus testing 
days 1-2.   
 





























































































Tissue Harvesting and Preparation  
All animals were re-anesthetized with an intraperitoneal injection of pentobarbital (80 
mg/kg).  Mice were perfused with 0.1M PBS (pH=7.4) followed by 4% 
paraformaldehyde fixative.  Brains were post-fixed with 4% paraformaldehyde for 
approximately 12 hours, and cryoprotected in phosphate-buffered 30% sucrose.  The 
brains were then embedded in optimal cutting temperature (OCT) medium (Sakura, 
Torrence, CA), frozen, and stored at -80°C.   Using a Microtome Cryostat (Richard-Allan 
Scientific, Kalamazoo, MI) the brains were sliced into 25 µm coronal sections and 
mounted onto sequential series gelatin-coated glass slides for histological analysis. 
 
Immunohistochemistry for Fibronectin in Brain  
Sections (spaced 100 µm apart) were stained for FN to assess how the absence of pFN 
correlated with the amount of FN in the injured brain.  Briefly, sections were rinsed in 
PBS, and then blotted and permeabilized in 8% goat serum and 0.1% tritonX-100 in PBS 
for 1 hr at room temperature.  Sections were then incubated overnight at 4°C with an 
antibody recognizing mouse FN (AB2033, 1:50, Chemicon, Temecula, CA).  Following 
rinsing in PBS, sections were incubated in a rhodamine-conjugated secondary antibody 
(Jackson ImmunoResearch) for 2 hours at room temperature.  The area of immunostained 
tissue was quantified for 1-2 representative brains at 3 and 7 days post-CCI using Image 
Pro® software (Media Cybernetics, Silver Spring, MD).  Briefly, the total area of 
positively stained tissue above a threshold intensity (set by the highest intensity for that 
brain’s immunohistochemical negative controls) was determined for each section.  The 
total area of FN+ tissue per section was then averaged for a given brain 
 
Lesion Volume Assessment 
Tissue sections were stained for Nissl with cresyl violet (Sigma-Aldrich, St. Louis, MO).  
The Cavalieri volume estimator (Rosen and Harry, 1990) with Stereo Investigator 
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software (Microbrightfield, Williston, VT) was used to determine the volume of the 
injury cavity (20-24 sections total at 200 µm increments per brain; coefficient of error < 
0.1).   
 
Identification of Apoptotic Cell Death and Phagocytic Cell Response 
Though apoptosis can persist long after the initial insult, the majority occurs within the 
first few days (Newcomb et al., 1999).  To assess apoptotic cell death at 1 and 3 days 
post-CCI injury, tissue sections were stained with TUNEL using the NeuroTACSTM II kit 
(Trevigen, Gaithersburg, MD).  Because we have previously found that phagocytic cells 
appear at the injury site at 3 and 7 days post-CCI injury, we probed for phagocytic cells at 
these time points.  Phagocytic cells were labeled with fluorescently tagged isolectin IB4, 
which binds to the terminal α-D-galactosyl residues on microglia and macrophages 
(Maddox et al., 1982; Pennell et al., 1994).  Under microscopic analysis cells that were 
both TUNEL+ and exhibited morphological characteristics of apoptosis (e.g., condensed, 
rounded cytoplasm and apoptotic bodies) were considered apoptotic; and cells that were 
both isolectin IB4+ and demonstrated a rounded, amoeboid shape were counted as 
phagocytic cells.  We did not distinguish between monocyte derived (blood-borne) 
macrophages and activated microglia.   
 
Quantification of Apoptotic and Phagocytic Cells  
Design-based stereology was used to quantify both the number of apoptotic cells in the 
injured cortex (defined as the area of cortical tissue within 1 mm from the cavity border) 
and the number of macrophages/activated microglia in both injured cortex and blood 
clots (which were often present at the injury site at 3 days post-injury).  The optical 
fractionator method (Gundersen, 1986; Sterio, 1984) with Stereo Investigator software 
(Microbrightfield) was employed to obtain these estimates (20-28 sections at 200 µm 
increments per brain; coefficient of error ≤ 0.1).   
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In Vitro Assessment of Fibronectin and Survival of Astrocytes 
Astrocytes were harvested from cortices of rat pups (post natal day 0-1), and allowed to 
mature in vitro.  Cultures were maintained in Dulbecco's modified eagle medium: 
nutrient mixture F-12 (DMEM/F12, 1:1, Invitrogen) supplemented with 10% goat serum 
(Invitrogen), which was replenished every 2-3 days, and cells were passaged when they 
reached 80-90% confluency (approximately every 5 days).  When cells were passaged for 
the tenth time, they were plated in plastic wells coated with either poly-l-lysine (PLL; 50 
µg/ml, n=4; Sigma-Aldrich) or FN (10 µg/ml, n=4; Invitrogen).  When cells reached 
confluency (after 2 days) media was replaced with DMEM/F12 only (without serum), 
which has been shown to induce apoptotic cell death for multiple cell types (Baehrecke, 
2005; Gibson, 1999; Kulkarni and McCulloch, 1994).  After 24 hours in serum-free 
media, cells were rinsed in PBS, fixed with 4% paraformaldehyde, and stained with 
calcein-AM to identify live cells and ethidium homodimer to identify dead or dying cells 
(Invitrogen).  Micrographs were taken under fluorescent microscopy of 5 regions within 
each well: center, “northwest”, “northeast”, “southwest”, and “southeast”, which were 
subsequently quantified to determine the percentage of dead/dying cells.  
 
Statistics 
A general linear model ANOVA, followed by Tukey’s pairwise comparisons (Minitab, 
State College, PA) were used to compare the following groups: 1- sham (for behavior 
studies only), 2- injured WT, 3- injured pFN null, and 4- injured pFN null + pFN IV, or 
for the in vitro portion, 1- astrocytes plated on PLL and 2- astrocytes plated on FN.  An 
alpha value of 0.05 was used to assess if the means were significantly different.  Data are 





Plasma fibronectin null mice lack fibronectin in blood and injured brain   
Because FN is crucial to organ formation in embryonic development, a conventional FN 
knockout animal is embryonically lethal (George et al., 1993).  Thus, the Cre-loxP 
system was employed to accomplish the deletion of FN in adult animals (Sakai et al., 
2001).  The FN gene in the liver of mice expressing Cre driven by an interferon- or pIpC- 
inducible Mx promoter was completely deleted upon receiving pIpC, thus eliminating the 
source of pFN (Sakai et al., 2001).  Western blots of plasma samples taken at 3 and 7 
days and 1 month following the final injection of pIpC confirm that the levels of FN in 
the pFN null mice are less than 2% of that found in WT mice (Figure 4.3).  To further 
confirm that any effects of the FN knockout on the brain injury response were due 
specifically to the absence of pFN, a subset of the pFN null mice received a single IV 
injection of pFN (~50mg/kg) 6 hours prior to the CCI injury.  Western blots of plasma 
samples taken shortly after the injury revealed that the level of FN in these mice was 













Figure 4.3: Fibronectin in blood plasma  
The amount of FN in the blood plasma in adult pFN null mice is less than 2% of the 
amount found in wild type littermates by 3 days after initiation of the knockout.  Injecting 
human pFN intravenously 6 hours prior to CCI injury restores the amount of FN in the 
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Following TBI, FN enters the brain during acute breaches in the BBB (Nag et al., 1997), 
thus the amount of FN in the bloodstream is proportional to the amount of FN in the 
injured brain tissue.  We have previously found that there is an increased amount of FN 
in the injury penumbra up to 7 days following CCI injury in mice (Tate et al., Submitted 
2006).  Immunolabeling for FN in the injured brain of pFN null mice at 1, 3 and 7 days 
post-CCI injury revealed that there are negligible levels of FN in the injured brain tissue 
of pFN null mice, which was confirmed by quantification at 3 and 7 days post-CCI injury 
(Figure 4.4).  This suggests that the majority of the FN in the injured brain is plasma 
borne.  While there is incomplete deletion of the FN gene in the brain (Sakai et al., 2001) 
and increases in FN gene expression have been observed at 3 days post-CCI injury 
(Natale et al., 2003), any contribution of cellular FN produced by neural cells, such as 
















Figure 4.4: Fibronectin in the injured brain  
Previous work showed that fibronectin is increased in the injured brain at acute time 
points following controlled cortical impact injury.  Immunolabeling for fibronectin 
revealed that the protein was found in injury penumbra for wild type animals (top, left), 
but not for pFN null mouse brains (top, right).  Cavity border is indicated by dotted line.  
Images taken at 3 days post-CCI injury; Scale bars = 100 µm;  Quantification of 1-2 
representative brains at 3 and 7 days post-CCI injury is shown in the bottom plot, 
confirming that there is not a noteworthy amount of  fibronectin positive tissue in injured 





































Plasma fibronectin null mice exhibit worse motor and cognitive performance 
following brain injury  
Motor behavior was assessed weekly (up to 10 weeks post-CCI injury) using the rotarod 
and beam walk tasks.  For the rotarod task, an injury deficit was only observed up to 7 
days post-CCI injury, and there were no differences between injured groups in gross 
motor ability (data not shown).  However, on the beam walk task the moderate impact to 
the frontoparietal cortex resulted in an injury deficit throughout the testing period for all 
injured groups compared to sham animals (n=19, p<0.05).  Interestingly, the injured pFN 
null group (n=10) performed significantly worse than both the injured WT (n=11, 
p<0.05) and pFN null + pFN IV (n=10, p<0.05) groups up to 4 weeks post-CCI injury on 
the 12 mm beam (Figure 4.5-top), and up to 9 weeks post-CCI injury on the more 
difficult 6 mm beam (Figure 4.5-bottom).  Moderate cortical injuries result in impaired 
spatial learning ability, likely due to secondary cell death and damage in the 
hippocampus.  Therefore, animals were tested on the Morris water maze (MWM) task at 
6 weeks post-CCI injury to assess spatial learning ability (12 day, 2 trials per day testing 
paradigm).  By testing days 9-10, the injured pFN null group (n=5) performed 
significantly worse than both the injured WT (n=5, p<0.01) and pFN null + pFN IV (n=3, 
p<0.01) groups, and were also significantly worse than the injured pFN null + pFN IV 
group (p=0.027) at testing days 7-8 (Figure 4.6).  While an injury deficit compared to 
sham animals (n=13) was observed for the injured WT (p<0.05) and pFN null groups 
(p<0.05), there was no statistical difference between the sham and injured pFN null + 
pFN IV groups.  Overall, the increased motor and cognitive deficits for the pFN null mice 



























Figure 4.5: Beam walk  
Injured mice deficient in plasma FN perform significantly worse compared to both 
injured WT mice and pFN null mice receiving an IV pFN injection on the 12 mm (top) 
and 6 mm (bottom) beam walk task. *p<0.05 pFN null-CCI vs. WT-CCI; §p<0.05 pFN 













































































Figure 4.6: Morris water maze  
At 6 weeks post-CCI, injured mice deficient in pFN perform significantly worse at the 
end of the testing period compared to both injured WT mice and injured pFN null mice 
receiving an IV pFN injection. Mean ± SEM; *p<0.01 pFN null-CCI vs. WT-CCI; 
§p<0.01 pFN null-CCI vs. pFN null-CCI + pFN IV, #p=0.03 pFN null-CCI vs. pFN null-
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Plasma fibronectin null mice have increased cell death following brain injury 
Lesion volume was quantified at 10 weeks post-CCI injury using Nissl staining and the 
Cavalieri estimator.  The lesion volume for the injured pFN null mice (8.7±1.9 mm3, n=4) 
was significantly higher than both the injured WT (4.2±0.6 mm3, n=4, p=0.003) and pFN 
null + pFN IV (4.0±0.8 mm3, n=3, p=0.004) groups (Figure 4.7).  Therefore, mice that 
only lack pFN (and thus FN in the injured brain) had lesions over two times as large as 
normal mice by 10 weeks post-injury, which is on the order a million of more cells lost in 
the pFN null brain.  Since the mechanism of tissue loss is important in understanding the 
response to injury, apoptotic cells in the ipsilateral cortex were identified at 1 and 3 days 
post-CCI injury using terminal deoxynucleotidyl-transferase-mediated biotin-dUTP nick 
end labeling (TUNEL) and morphological criteria to distinguish apoptosis from necrosis.  
Quantification of apoptotic cells, obtained using unbiased stereology, revealed that the 
injured pFN null mice had increased cortical cell death.  At 3 days-post CCI, the number 
of apoptotic cells in the injured cortex of pFN null mice (29,700±11,720, n=5) was 5-fold 
higher than for injured WT mice (5,800±4,910, n=6, p=0.002 and almost 3-fold higher 














Figure 4.7: Lesion volume   
At 10 weeks post-CCI injury, the lesion volume of injured mice deficient in pFN (pFN 
null-CCI) is significantly larger than injured WT mice (WT-CCI, *p=0.003) and pFN-
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Figure 4.8: Apoptotic cell death in the injured cortex 
At 3 days post-CCI injury, the amount of apoptotic cell death in the injured cortex for 
deficient in pFN (pFN null-CCI) is significantly larger than injured WT mice (WT-CCI, 
*p=0.002) and pFN-null mice receiving an IV pFN injection (pFN null-CCI + pFN IV, 
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Plasma fibronectin supports survival of astrocytes in vitro 
While neurons bound to FN have been shown to have delayed apoptosis upon serum 
withdrawal in vitro, we investigated whether this is also true for astrocytes.  Astrocytes 
plated on FN (n=4) had significantly less cell death 24 hours after serum withdrawal 
versus those plated on PLL (n=4, p=0.04) (Figure 4.9).  It appeared that as cells 
underwent cell death, they became detached from the surface, and this detachment started 
at the periphery of the well, then moved towards the center.  To better account for dead 
floating cells that had been rinsed away by the time of staining, we quantified the amount 
of cell death in the center of the well (micrographs in Figure 4.9) and again found that 
astrocytes plated on FN had significantly less cell death 24 hours after serum withdrawal 










Figure 4.9: Fibronectin rescues astrocytes in vitro 
Astrocytes plated on fibronectin had significantly less cell death 24 hours after serum 
withdrawal versus those plated on poly-l-lysine.  Representative micrographs of the live 
(green) and dead/dying (red) cells remaining in the center of the well are shown above 
the plot.  Scale bars = 100 µm; This data along with reports of similar trends for neurons 
indicate that direct binding of neural cells to fibronectin can prevent cell death.  *p=0.04, 











Entire Well Center of Well
















Plasma fibronectin null mice have decreased levels of phagocytic cells following 
brain injury 
To determine if FN is involved in an inflammatory response after TBI similar to 
peripheral wound healing, the number of phagocytic cells was quantified.  Cells that were 
both isolectin IB4 positive and exhibited a rounded morphology were considered 
phagocytic cells, which could be either monocyte-derived macrophages or activated 
microglia, and were quantified using unbiased stereology.  For all injured groups, these 
cells were present in blood clots at 3 days post-CCI injury and in the cortical injury 
penumbra at both 3 and 7 days post-CCI injury.  For all the injured groups (pFN null, 
WT, pFN null + pFN IV), about half of the mice had blood clots at the injury site at 3 
days, containing the large majority of phagocytic cells (likely blood macrophages), and 
there was no difference in the number of phagocytic cells between the injured groups at 
this time point (p>0.8, data not shown).  Furthermore, Sakai et al. reported that pFN null 
and WT mice had the same number of macrophages in the injured brain 2 days following 
ischemia (Sakai et al., 2001).  However, while the number of phagocytic cells decreases 
by 7 days post-CCI injury for all groups, there were significantly less macrophages / 
activated microglia in the injury periphery for the pFN null mice (10,930±8,800, n=4) 
compared to the WT littermates (45,920±22,680, n=5, p=0.029).  Also, plasma FN null 
mice that received pFN IV had increased numbers of macrophages / activated microglia 
in the injury periphery (40,000±13,830, n=4, p=0.083) compared to mice without pFN 
(Figure 4.10).  This suggests that while phagocytic cells are available at acute time points 
(primarily from the blood), the pFN may aid in recruiting or retaining phagocytic cells to 
the injured cortex, which underscores the role of FN in phagocyte adhesion, migration, 

























Figure 4.10: Phagocytic cells in the injured brain 
At 7 days post-CCI, the number of phagocytic cells in the injured cortex for mice 
deficient in plasma FN (pFN null-CCI) is significantly lower than for injured WT mice 
(WT-CCI, *p=0.029), and the addition of plasma FN prior to injury seems to reverse this.  
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Finally, to determine if FN is involved in forming or stabilizing the glial scar, we stained 
for glial fibrillary acidic protein (GFAP) to identify reactive astrocytes, which are the 
dominant cell type of the glial scar.  We found no differences between the injured groups 
in either the density or morphology of GFAP+ cells up to 7 days post-CCI injury (data not 
shown), indicating these cells are able to proliferate and migrate independent of pFN.   
 
Discussion 
We utilized conditional pFN knockout mice to investigate the role of pFN in TBI.  
Because the deletion of the FN gene in the liver occurs in adult animals, these mice 
develop normally and without the complications of compensatory mechanisms, such as 
increased expression of other ECM proteins (Sakai et al., 2001).  We found that 
following experimental TBI, mice deficient in pFN had significantly worse motor and 
cognitive ability, significantly more cell death, and significantly less retention of 
phagocytic cells compared to WT mice.  Furthermore, replacing the knocked out pFN 
(with a single IV injection of human pFN 6 hours prior to the injury) restored their 
behavior performance, cell death profiles, and levels of phagocytic cells to that of WT 
animals.  The fact that the pFN replacement was able to rescue the knockout mice shows 
that these differences were due to specifically to pFN.  Collectively, these data show that 
FN is neuroprotective to the traumatically injured brain.   
 
While there were significant differences in apoptotic cell death, it is not clear if this is 
due to a direct binding of injured neural cells to pFN.  In vitro studies of various cell 
types reveal that binding to FN via the α5β1 integrin leads to anti-apoptotic signals 
including increases in Bcl-2 expression (Fukai et al., 1998; Zhang et al., 1995).  For 
neural cell types, Gibson, et al., showed that neurons plated on FN had less apoptotic cell 
death after serum withdrawal, and FN induced anti-apoptotic signaling via α5β1 integrin 
binding (Gibson et al., 2005).  In addition, we found that pFN rescued astrocytes from 
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cell death after serum withdrawal.  Together, this in vitro evidence shows that direct FN-
integrin binding to neural cells initiates anti-apoptotic signaling.   Both neurons and glial 
cells express α5β1 in the adult brain (King et al., 2001), thus FN in the injured tissue may 
be binding directly to damaged neural cells to reduce apoptosis.  Based on our findings 
alone, we cannot assess whether these cells are directly binding to the FN in the injured 
brain, or FN is helping the injured environment through an alternative mechanism which 
subsequently reduces cell death.   
 
Another potential mechanism of protection for FN is through aiding in the inflammatory 
response to injury.  Though the inflammatory response to brain injury is often considered 
detrimental, its beneficial roles are becoming more appreciated (Correale and Villa, 2004; 
Morganti-Kossmann et al., 2002; Schwartz, 2000).  Furthermore, the use of progesterone 
(a promising clinical treatment for TBI) has been shown to improve neurological 
outcome in injured rats and is associated with an increase in macrophages / activated 
microglia (Grossman et al., 2004; Shear et al., 2002).  In this study, we found that 
animals that had enhanced motor and cognitive deficits and increased cell death also had 
fewer phagocytic cells in the injury penumbra at 7 days post-injury.  The role of 
phagocytes in initial clearance of injured tissue is certainly important in reducing the 
spread of cell death to neighboring tissue by clearing potentially toxic components of 
necrotic cells.  Regarding the association of FN with macrophages / activated microglia, 
it is likely that FN is aiding in phagocytosis.  The relationship between macrophages and 
FN has been studied to a large extent with respect to wound healing mechanisms (Clark, 
1988; 1990; Clark et al., 1982; Grinnell, 1984; Martin et al., 1988; Reese et al., 1982; 
Tonnesen et al., 2000).  Fibronectin is known to promote adhesion and migration of 
macrophages, and acts as an opsonin, particularly with gelatinous material, such as 
damaged tissue (Grinnell, 1984; Martin et al., 1988).  Furthermore, binding of microglial 
cells to FN promotes adhesion, migration, and proliferation (Liao et al., 2005; Nasu-Tada 
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et al., 2005), and the activation of microglia is associated with elevated expression of 
integrins which bind FN (Milner and Campbell, 2003).  Thus, FN may also support the 
recruitment and expansion of microglia in response to traumatic injury.  Binding of 
macrophages to FN leads to the release of the pro-inflammatory cytokine TNFα (Hoyte 
et al., 1997), which has been shown to be beneficial to for long-term repair and recovery 
following experimental TBI (Scherbel et al., 1999), and binding of microglia to FN leads 
to increased production of the anti-inflammatory cytokine TGFβ, and nerve growth factor 
(Liao et al., 2005).  Thus, FN may increase the production of neuroprotective or 
neurotrophic molecules in the injured brain tissue.   
 
Since the absence of pFN led to increased impairment following TBI, a logical inference 
is that excess or super-physiologic levels of FN in the brain may enhance recovery.  
Furthermore, in experimental brain ischemia, IV administration of functional FN peptides 
led to reduced lesion size and improved neurological outcome (Yanaka et al., 1996; Zhao 
et al., 2005).  However, the IV injections of pFN given in this study restored less than 
normal concentrations of FN in the blood; and we found that these mice were statistically 
the same as WT mice for the outcome measures assessed.  Thus, the protective 
mechanisms involving FN may require less than physiologic levels.  However, in 
examining the lesion size of animals from the study in Chapter 2, we found that mice 
receiving intracranial injections of the FN (100 µg/ml) and collagen I (1 mg/ml) scaffold 
at 7 days post-injury had significantly decreased lesion volume at 9 weeks post-injury 
(Figure 4.11).  Note that these injections were given after the closing of the BBB and at a 
time when the amount of endogenous FN is approaching uninjured levels.  Perhaps the 
presence of the FN in the injured brain at this time was able to promote survival of cells 
in the injury penumbra and reduce the ongoing spread of the lesion.  Another potential 
explanation is that the scaffold encouraged migration of endogenous cells into the injury 
cavity.  Additional studies involving administration of FN – either intravenously at acute 
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time points post-TBI (while the BBB is more permeable) or at sub-acute time points 
(either intracranially or in conjunction with re-opening the BBB) to maintain higher 
levels of FN in the injured brain – are warranted to address the potential use of FN in a 
treatment paradigm.  In any case, a better understanding of the components and 
mechanisms involved in brain injury are critical steps to developing more effective 
treatment strategies.  Moreover, the reparative/protective nature of FN in the brain may 
potentially be exploited for other neurological disorders that do not involve breaches in 
the BBB.  Given the complex and dynamic microenvironment of the traumatically 
injured brain, it may be beneficial to use a multi-level treatment approach, such as 














Figure 4.11 Lesion volumes following intracranial injection of fibronectin 1 week 
post- injury 
Injured C57BL6 mice received intracranial injections of a scaffold containing FN (100 
µg/ml) and collagen I (CnI; 1 mg/ml) at 1 week post-CCI injury.  By 9 weeks post-CCI 
injury, treated animals had a significant reduction in lesion volume compared to untreated 
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The presence of FN in the injured brain has been identified by many groups following 
both clinical and experimental TBI.  Since the majority of this FN is plasma borne, it was 
previously unclear if or how the brain was actively utilizing this protein.  We have shown 
here that FN in the traumatically injured brain is protective against cell death, which 
ultimately correlates with behavioral function.  Previous work by Sakai et al. showed that 
pFN is also protective following cerebral ischemia (Sakai et al., 2001).  This indicates 
that when FN is available in the injured brain (i.e. there is a breach in the BBB), this 
protein is utilized in a reparative fashion.  Therapeutic exploration of endogenous repair 
systems may be a promising strategy for improving outcome after brain injury. 
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CHAPTER 5  
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Tissue Engineering Strategies Improve Cell Transplantation into the Injured Brain 
Cell transplantation is an appealing treatment strategy for disorders of the central nervous 
system (CNS), and has already shown promise in the clinic for treating traumatic brain 
injury (TBI) (Seledtsov et al., 2005).  Exploiting cells for transplantation offers huge 
potential, ranging from using these biologically active systems to produce and secrete 
specific neurotrophic factors to replacing lost cells.  Advantages of transplanting cells 
include the ability to target multiple mechanisms and the ability to provide a sustained 
treatment.  Furthermore, cells, particularly stem cells, can adapt to their environment, 
thus are able to evolve with the ever-changing pathologic brain.  Using stem or 
progenitor cells also offers the opportunity to have either “off-the-shelf” treatments (e.g., 
renewable cell source such as embryonic stem cells) or autologous grafts (e.g., bone 
marrow-derived mesenchymal stem cells).  Cell source is also important when 
considering the host immune response to the grafted cells.  Again, autologous stem cells 
as well as embryonic stem cells (due to their relatively low levels of major 
histocompatibility complex) would be preferred, and work is currently underway in our 
laboratory, as well as others, to push these pluripotent stem cells towards neural 
phenotypes.  While many groups are exploring various cell types for treating brain injury 
or disease, few focus on optimizing transplant conditions.   
 
One major limitation to cell transplantation has been poor survival of donor cells in the 
injured or diseased brain.  Our goal is to improve the survival and integration of donor 
cells in an effort to enhance recovery.  Fetal tissue pieces grafted into the injured brain 
have shown promising results, likely because these are relatively stable grafts that are less 
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vulnerable to cell death and contain critical components that aid in repair.  However, 
limitations to fetal tissue transplants include inadequate availability and ethical concerns, 
technical difficulties keeping tissue pieces viable in vitro, and potentially invasive 
delivery of a three-dimensional implant.  These limitations can be overcome by 
engineering a tissue-like construct based on core components of the developing (fetal) 
brain tissue: neural stem cells (NSC), extracellular matrix (ECM) proteins, and in situ 
three-dimensionality.  We expect that this is an improvement over cell suspension 
transplants due to both the ability to control the environment of the donor cells and the 
presence of components that may be crucial to graft success in rescuing damaged tissue.   
 
In this work, we examined the effect of using a tissue engineered construct containing 
NSC plus an ECM protein-based scaffold on donor cell survival and integration, and 
cognitive behavior or treated animals following transplantation into the traumatically 
injured brain.  The two ECM-based scaffolds investigated were fibronectin-collagen I 
(FN/CnI) and laminin-collagen I (LN/CnI).  Fibronectin and LN were utilized because of 
their critical involvement in the developing brain.  In addition to using proteins that 
support donor cells through cell-matrix signaling, we wanted the ability to deliver a tissue 
construct that was three-dimensional in situ, but could be delivered in a minimally 
invasive fashion.  Thus, CnI was chosen for its thermally-reversible properties.   
 
We found that both FN and LN containing scaffolds could be injected as a viscous liquid, 
and form a gel upon reaching physiologic temperatures, thus achieving the goal of a 
three-dimensional microenvironment for the donor cells with minimally invasive 
delivery.  We also found that donor cells in both scaffolds examined had improved 
survival compared to cells transplanted alone.  Interestingly, this effect was not observed 
at the early post-transplant time points examined (1 and 3 weeks), but it was evident by 8 
weeks post-transplant.  While initially donor cell survival in all groups was similar (~3-
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5%), the rate of subsequent cell death over the next several weeks was slowed for the 
groups that received the tissue engineered scaffolds.  This may be due to a number of 
reasons, including selection of a more robust cell type(s) during the very early post-
transplant period or improving the condition of the host tissue, thus creating a more 
favorable environment for donor cell survival.  From a clinical standpoint, it would be 
ideal to deliver this type of treatment with only a single injection, thus encouraging 
longer term graft survival will be crucial.   
 
In comparing the two scaffolds examined, the LN/CnI scaffold was better at maintaining 
cell survival than the FN/CnI scaffold.  Also, the group that was treated with the 
NSC+LN/CnI scaffold showed significant improvement in cognitive ability, while the 
other treatment groups only had a modest affect on this cognitive recovery.  Though both 
FN and LN are critical to neural development, are increased after TBI, and support 
migration and adhesion of NSC in vitro, the LN-based scaffold was more advantageous 
through mechanisms that are not fully understood.  This response may be partially 
explained in light of in vitro data demonstrating NSC had increased migration on LN 
compared to FN, which may result in enhanced integration in vivo with host tissue.  
However, no migration differences in the brain were observed between the treatment 
groups in the study presented here, underlying the complexities of the post-injury 
environment in vivo.  Another difference that we previously observed in vitro is that NSC 
plated on LN had a slight, yet significant increase in differentiation into neuron-like cells.  
But, again this did not reflect the in vivo setting, as we did not identify any NeuN+ donor 
cells.  Furthermore, a higher percentage of neurons does not necessarily translate to better 
outcomes, as glial cells may provide sustained and sufficient neurotrophic support.  In 
addition, it is unclear in any neural transplant setting (clinical or animal) whether 
transplanted neurons integrate into existing neuronal circuits in a functional manner.  
Future in vitro studies with LN and NSC and/or injured tissue may help identify 
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mechanisms by which LN improves survival of NSC.  Our laboratory has developed an 
in vitro model of neural injury which consists of neurons and astrocytes cultured three-
dimensionally in Matrigel®.  Efforts are underway to use this as a test bed for various 
transplant conditions (Cullen et al., In preparation 2006), though the use of Matrigel® 
complicates studies with LN and alternatives are being considered.  As far as future work 
with applying tissue engineering strategies for TBI, the use of a LN-based scaffold is 
recommended.   
 
Given the technical difficulties associated with our tissue engineering work, it might be 
necessary to make a case for using tissue engineering in our model of TBI at all, 
especially since transplanting NSC into the striatum also promotes functional recovery.  
Addressing the technical issues first, these are largely due to the fact that we are injecting 
viscous materials into a very small cavity.  The volume we deliver is based on volume 
estimates of the cavity made using histological sections.  In a live animal, however, the 
“cavity” is sometimes filled with fluid, making the injection more difficult, and 
increasing variability.  Work in higher-order mammals (with larger injuries) may 
alleviate some of these issues, though careful consideration should be given to injection 
volumes into damaged tissue.  As far as the promising results we have had with striatal 
injections, this may be due to the fact that a common feature of both transplant paradigms 
was an extracellular support for transplanted cells, whether it was from native striatal 
tissue or a scaffold co-delivered with the cells.  From a clinical standpoint, it is less 
invasive to transplant into cortical areas versus deeper brain structures, and transplanting 
into non-injured tissue distal to the injury should be avoided if transplants at the site of 
injury are comparably effective.  Though clinical brain injuries have much more 
widespread damage than the focal injuries modeled experimentally, cortical injury is a 
common feature seen in blunt (non-penetrating) trauma.  In the work presented here we 
delivered construct volumes that would potentially “fill” the injury cavity.  However, due 
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to the increased scale and scope of clinical TBI, this may be difficult, requiring large 
amounts of both cells and scaffold materials.  However, our aim is to control the 
microenvironment of the donor cells.  Thus, using small volumes will still be appropriate.  
Perhaps at the time of transplant, multiple injections could be delivered proximal to the 
injury site(s).  These types of considerations are also important when expanding tissue 
engineering techniques to other CNS injuries and diseases.  Tissue engineering strategies 
increase donor cell survival and can be exploited to augment cell transplantation for 
many disorders, including spinal cord injury, ischemia, and Parkinson’s disease.  Our 
work in experimental TBI can be considered a representative (though extremely 
complex) in vivo model for identifying candidate scaffolds (and cells) for use in a tissue 
engineered treatment approach.   
 
To this end, further investigation is warranted that may address some of the questions 
raised by the work presented here.  Firstly, it cannot be ignored that a significant amount 
of donor cell death occurs within the first week following transplantation.  Obviously, 
since low percentages of surviving cells are seen in multiple transplant settings, a 
reasonable strategy may be to transplant more cells.  Furthermore, it has been 
demonstrated that increasing the number of cells transplanted actually improves the 
percentage that will survive (Saporta et al., 1999).  However, transplanting more cells is a 
potentially costly solution, is limited from a technical standpoint, and may not be feasible 
when using autologous cell sources; thus demanding efforts to maximize the percentage 
of survival cells in other ways.  Elucidating some of the mechanisms governing this acute 
cell loss is necessary (e.g., with the in vitro test bed described above) and may lead to 
engineering a scaffold that actively reduces the observed cell death.  Along the lines of 
more precisely engineering scaffolds, using polymers, such as methylcellulose, may 
provide more control over specific design criteria and could be tailored to direct cell 
function.  Though we may not currently know enough about the needs of the injured 
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brain (which is partly the motivation for using multipotential cells), as more information 
regarding successful transplants becomes available, having a moldable scaffold design 
will be beneficial.  Additionally, the next phase of this work will also need to address the 
use of alternate cell sources that are more clinically feasible, such as embryonic stem cell 
lines or bone marrow-derived stem cells.  To summarize, we have made significant 
progress by using tissue engineering to improve cell transplantation therapy for TBI.  We 
need to address issues about how best to further enhance cell survival and integration, 
partially with the use of in vitro models, and utilize this information to improve our tissue 
engineered construct design.   
 
Fibronectin and Laminin are Involved in Host Response to Brain Injury 
In addition to investigating how the host environment influences donor cells, it is 
important to understand how ECM-based scaffolds affect the host environment.  Though 
we intended to exploit these proteins for their ability to affect NSC function, FN and LN 
may also directly benefit the injured brain.  Both FN and LN are involved in neural 
development, and these proteins are found in increased levels following brain injury.  
Furthermore, the brain may be utilizing these proteins in a reparative or regenerative 
fashion after injury.  Thus, utilizing FN and LN could both directly improve survival and 
function of donor cells and augment endogenous repair mechanisms, thereby further 
contributing to an environment within the host brain that is more amenable to donor cells.   
 
While these proteins had been found in increased levels following clinical and 
experimental TBI, their presence had not been examined using an experimental model of 
blunt trauma, which is the most common type of clinical TBI.  Since we were interested 
in investigating these proteins in such a model, we needed to first establish the 
distribution pattern in injured brains using an in vivo model of blunt trauma.  Thus, we 
investigated the spatiotemporal profile of FN and LN following controlled cortical impact 
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(CCI) injury.  Increased FN+ and LN+ tissue was observed up to 14 days post-CCI injury, 
and the levels were significantly higher than sham controls at 3 days post-CCI injury.  
The FN+ staining appeared in the extracellular tissue adjacent to the injury, including 
blood clots at the site of impact found at acute time points.  The LN+ staining was 
primarily located in blood vessels in the tissue adjacent to the injury.   
 
We also wanted to determine if FN and LN correlated with support cells to begin to 
elucidate potential roles for these proteins in the injured brain.  We found that FN+ tissue 
was populated with macrophages and/or activated microglia, indicating a role for FN in 
aiding in the functions of these phagocytic cells.  Also, reactive astrocyte processes were 
found wrapped around the majority of LN+ vessels, implying LN may be involved in 
angiogenesis and/or reformation of the blood-brain barrier (BBB). 
 
The co-spatialization of the increased ECM proteins with supporting cells warrants 
further investigation into their hypothesized beneficial role in the injured brain.  For 
example, the tight spatial correlation of LN+ vessels with reactive astrocytes we observed 
and the correlation of the time course of the increases in LN with the biphasic opening of 
the BBB (Baskaya et al., 1997) imply a role in BBB repair or reformation.  Further 
experiments should be conducted which alter the amount of LN in the injured brain and 
investigate the resulting effects on factors related to re-establishing the vasculature and 
BBB (e.g., angiogenic activity and BBB permeability).  While these types of experiments 
will not provide direct causality information, they address specific functions of LN in the 
injured brain.  The effects of LN on BBB function after injury could be examined by 
providing supernormal levels of LN to the injured brain (via either intravenous or 
intracranial administration).  Alternatively, the amount of available LN in the injured 
brain could be decreased by reducing expression of LN RNA with short interference 
RNA or by blocking LN specific integrin dimers (e.g., α6β1) to prevent LN from binding 
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to cells.  However, both of these options have limitations, including inefficient deletion of 
LN or LN-integrin binding (particularly in vivo) and potentially disturbing other 
molecules, cells, or pathways, careful interpretation of the results.  An elegant way to 
study the role of LN would be with a conditional LN knockout; however, this transgenic 
animal is not currently available.  On the other hand, a conditional FN knockout is 
available, which allowed us to further examine the role of this ECM protein in the injured 
brain. 
 
To summarize this work, we evaluated the spatiotemporal profile of two ECM proteins 
involved in neural development.  We were the first to evaluate these proteins using a 
model of blunt trauma, which is the most common type of clinical TBI, and is a widely 
used as an experimental model.  We also propose potential mechanisms of action for the 
increased amounts of FN and LN based on spatial localization with cells and integrating 
with previous evidence from the literature.  The role of FN in TBI was subsequently 
further investigated.   
 
Fibronectin is Neuroprotective in Traumatic Brain Injury 
Fibronectin has been found to increase in the traumatically injured brain, though its 
functions were not known.  Furthermore, since the majority of FN enters the brain from 
the blood (during breaches in the BBB), it was not known if the protein was actively 
contributing to the injury response.  We investigated for the first time the role of FN in 
the traumatically injured brain utilizing adult, conditional plasma FN knockout (pFN 
null) mice.  We found that injured pFN null, when mice compared to injured wild type 
(WT) mice, had significantly more severe motor and cognitive deficits, significantly 
more apoptotic cell death at acute time points, significantly larger lesion volumes by 10 
weeks post-injury, and significantly less phagocytic cells in the injured cortex at 1 week 
post-injury.  Furthermore, a single intravenous injection of pFN into pFN null mice prior 
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to injury restored the above functions to that of injured WT mice.  These results indicate 
that FN is neuroprotective to the traumatically injured brain.   
 
Based on our findings, two potential mechanisms are proposed for how FN is beneficial 
in the injured brain.  Firstly, FN could be providing an anti-apoptotic signal for damaged 
neural cells.  Previous in vitro work has shown that FN is anti-apoptotic for several cell 
types, including neurons, and that binding of FN to α5β1 integrins leads to increased 
production of the anti-apoptotic molecule Bcl-2.  Here we showed that FN also promotes 
the in vitro survival astrocytes, which outnumber neurons 10:1, and whose function in the 
brain is an important part of normal and restorative physiology.  In injured pFN null 
mice, we observed significantly more apoptotic cell death at acute time points and lesions 
that were twice as large compared to injured mice that do not lack FN.  Since neurons and 
glial both express the α5β1 integrins in the adult brain (though FN is essentially absent in 
the normal adult brain), these cells may be binding to FN after injury.  Thus, FN may 
provide a direct survival (i.e. anti-apoptotic) signal to cells in the injury penumbra.   
 
A second potential mechanism identified in this work is that FN promotes phagocytosis 
of dead tissue, thus helping to reduce the spread of cell death due to the toxic 
environment created by necrosis.  We found that FN is involved in retaining phagocytic 
cells in the tissue bordering the lesion.  This observation was noted at one week post-
injury which is after the majority of the initial clearance occurs.  Due to the fact that 
several of the injured animals had blood clots, we could not tease out differences in 
phagocytic cells in more acute time points.  However it is likely FN is being exploited by 
phagocytic cells at the early time points given the evidence for FN in supporting the 
adhesion, migration and proliferation of both macrophages and microglia, and the role of 
FN as an opsonin for the removal of tissue debris.  In addition, FN may also have a role 
in later time points after injury since FN promotes secretion of beneficial factors in 
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microglia, which may aid in repair or regeneration.  These processes also promote cell 
survival, indicating FN may decrease apoptosis via indirect pathways.  A combination of 
these mechanisms likely accounts for the striking differences between injured mice 
having or lacking pFN. 
 
We have demonstrated that FN is neuroprotective, and specifically contributes to cell 
survival and retention of phagocytic cells following experimental TBI.  We have 
presented potential processes occurring at the cellular and molecular levels, however 
further investigation at the intracellular level can further direct treatment strategies.  
Focusing on the role of FN with phagocytic cells there are three main potential avenues 
of action requiring further investigation: 1- FN promotes migration, adhesion and/or 
proliferation of macrophages and/or microglia, 2- FN acts as an opsonin, and 3- FN 
increases secretion of neurotrophic factors.  The next phase of this work will begin to 
address these potential actions, and the conditional pFN knockout could again be 
exploited to test all of these hypotheses.  For example, to determine if FN promotes 
opsonization in the injured brain, we can measure the extent to which phagocytic cells are 
engaging in phagocytosis in injured pFN null mice versus wild type mice.  Since active 
phagocytosis requires increased alterations to the cytoskeleton, this could be identified 
with a marker that specifically binds to filamentous actin (e.g., phallacidin).  In addition, 
investigating these events in vitro may help identify specific mechanisms without the 
complications of competing factors and processes that arise in vivo.  And, isolating 
specific signaling molecules may be more straightforward with in vitro preparations.  
While all three of the aforementioned roles for FN with phagocytic cells have been 
examined in vitro, this has not been done in the presence of injured brain tissue, which 
has unique properties.  For example, if cultured macrophages engulf injured neural tissue 
or cells in vitro, we can investigate if this is enhanced by the addition of FN, and begin to 
elucidate the specific signaling molecules involved.   
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Given the fact that we determined pFN is neuroprotective in TBI and previous work with 
conditional pFN knockout mice revealed it is also neuroprotective in cerebral ischemia, a 
logical assumption is that FN may be beneficial in a treatment paradigm.  Indeed, 
intravenous injections of functional FN peptides have been found to be beneficial in 
experimental cerebral ischemia.  In the work presented here, the recovery of injured mice 
with sub-physiologic levels of FN was comparable to injured mice with normal levels for 
the outcome measures we examined.  This indicates that the system may be saturated, and 
super-normal levels may not be effectively utilized by injured brain tissue.  Future work 
with this project includes delivering FN (protein or peptides) to wild type animals at 
acute time points following TBI via intravenous injections, thus allowing the FN protein 
or peptides to enter via the normal route during an increased permeability of the BBB.  
However, it may be more beneficial to provide FN at sub-acute time points, when the 
endogenous levels have decreased towards normal amounts.  We have shown that injured 
wild type mice that received an intracranial injection of a FN-containing scaffold at 1 
week post-injury had significantly decreased lesion volume compared to untreated mice.  
Since intracranial delivery is more invasive than intravenous routes, FN could also be 
delivered at post-injury time points when the BBB has already resealed by exploiting 
agents that temporarily increase BBB permeability.  This technique could also be used to 
provide FN to the brain in disorders that are not associated with opening of the BBB.  
Future work for this project will include administering FN protein or peptides after 
endogenous post-TBI levels have been restored to normal in an expanded effort to 
examine the potential for FN in a treatment paradigm.  Moreover, studies investigating 
super-physiologic amounts of FN also increase our understanding of the relationship of 
FN with injured brain tissue.  A better appreciation of the injury response at multiple 
levels can improve treatment efforts, including combinatorial therapies, to repair the 
injured brain and enhance functional recovery of brain injured patients.   
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In conclusion, we determined that FN is neuroprotective to the injured brain; specifically 
FN decreases cell death and increases the presence of phagocytic cells.  Elucidating these 
mechanisms contributes to a better understanding of the complex pathology of TBI, 
which ultimately improves treatment strategies.  In light of the complicated and evolving 
endogenous response to TBI, it is likely that multi-targeted treatment strategies will be 
required.  One promising treatment strategy is cell transplantation, partially because it 
utilizes biologically active, adaptable systems that can respond to the needs of the injured 
brain.  We have showed that we can improve the survival of NSC transplanted into the 
injured brain by supporting the cells with a FN or LN based scaffold, and the NSC co-
transplanted within a LN scaffold enhance cognitive recovery.  Improving survival and 
integration of transplanted cells is a critical step for treating many disorders and diseases 
of the CNS.  The dissertation work presented here has broad applications, benefiting the 
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